var title_f41_53_42832="Canagliflozin: Drug information";
var content_f41_53_42832=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Canagliflozin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F16431883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidiabetic Agent, Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor;",
"     </li>",
"     <li>",
"      Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F16431880\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Invokana&trade;: FDA approved March 2013; anticipated availability is April 2013. Consult prescribing information for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F16431885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Treatment of type 2 diabetes mellitus (noninsulin dependent, NIDDM) as an adjunct to diet and exercise as monotherapy or in combination therapy with other antidiabetic agents to improve glycemic control",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 88901 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-217.117.136.88-094BD8D684-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_53_42832=[""].join("\n");
var outline_f41_53_42832=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16431883\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16431880\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16431885\">",
"      Use",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/88901\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/88901|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_53_42833="Abdominal paragonimiasis";
var content_f41_53_42833=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F53976&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F53976&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 603px\">",
"   <div class=\"ttl\">",
"    Abdominal paragonimiasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 583px; height: 261px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hepatic paragonimiasis in a two-year-old female with epigastric pain and remittent fever for about two months.",
"    <br>",
"     (A) Plain MDCT scan shows slightly hypodense lesion with heterogeneous attenuation and obscure margin in left lateral lobe.",
"     <br>",
"      (B) Contrast-enhanced MDCT scan at portal venous phase shows multilocular lesion with enhanced septa. The margin and internal detail are clearly demonstrated. Some of the cysts in the lesion are mutually connected.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Reproduced from: Li XM, Yu JQ, Yang ZG, Chu ZG, Peng LQ, Kushwaha S. Correlations between MDCT features and clinicopathological findings of hepatic paragonimiasis. Eur J Radiol 2011. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_53_42833=[""].join("\n");
var outline_f41_53_42833=null;
var title_f41_53_42834="Silver nitrate: Drug information";
var content_f41_53_42834=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Silver nitrate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?42/28/43459?source=see_link\">",
"    see \"Silver nitrate: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/46/20194?source=see_link\">",
"    see \"Silver nitrate: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F221080\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Topical;",
"     </li>",
"     <li>",
"      Cauterizing Agent, Topical;",
"     </li>",
"     <li>",
"      Topical Skin Product, Antibacterial",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F221068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Antiseptic, wound cauterization:",
"     </b>",
"     Topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Sticks: Apply to mucous membranes and other moist skin surfaces only on area to be treated",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Topical solution: Usual: Apply a cotton applicator dipped in solution on the affected area 2-3 times/week for 2-3 weeks.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F221076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/46/20194?source=see_link\">",
"      see \"Silver nitrate: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Antiseptic, wound cauterization:",
"     </b>",
"     Topical: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F221069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F221055\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Applicator sticks, topical: Silver nitrate 75% and potassium nitrate 25%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical: 0.5% (960 mL); 10% (30 mL); 25% (30 mL); 50% (30 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F221041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F221057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Applicators are",
"     <b>",
"      not",
"     </b>",
"     for ophthalmic use. If applicator sticks are used on dry skin, dip the applicator tip in water immediately before use.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F221056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Astringent, cauterization of wounds, germicidal, removal of granulation tissue, corns and warts",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F221078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Burning and skin irritation, staining of the skin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Methemoglobinemia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F221060\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to silver nitrate or any component of the formulation; not for use on broken skin, cuts, or wounds",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F221045\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Chemical burn: Silver nitrate is a caustic agent and inappropriate use may cause chemical burns. Skin contact time with applicator sticks should be extremely short when used in neonates or on thin delicate skin contact.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Skin discoloration: Prolonged use may result in skin discoloration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Do not use applicator sticks on the eyes.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6222926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Misc",
"     </b>",
"     (Arzol Silver Nit Applicators External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75-25% (100): $43.08",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Silver Nitrate External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (30 g): $36.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Silver Nitrate External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.5% (960 mL): $25.38",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10% (30 mL): $51.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25% (30 mL): $77.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50% (30 mL): $107.50",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Mova Nitrat Pipette (PL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F221044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Free silver ions precipitate bacterial proteins by combining with chloride in tissue forming silver chloride; coagulates cellular protein to form an eschar; silver ions or salts or colloidal silver preparations can inhibit the growth of both gram-positive and gram-negative bacteria. This germicidal action is attributed to the precipitation of bacterial proteins by liberated silver ions. Silver nitrate coagulates cellular protein to form an eschar, and this mode of action is the postulated mechanism for control of benign hematuria, rhinitis, and recurrent pneumothorax.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F221059\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Because silver ions readily combine with protein, there is minimal GI and cutaneous absorption of the 0.5% and 1% preparations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Highest amounts of silver noted on autopsy have been in kidneys, excretion in urine is minimal",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9888 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-180.241.123.62-C1AFB1FE5C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_53_42834=[""].join("\n");
var outline_f41_53_42834=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221080\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221068\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221076\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221069\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221055\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221041\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221057\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221056\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221078\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221060\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221045\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300040\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6222926\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323840\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038828\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221044\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221059\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9888\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9888|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?42/28/43459?source=related_link\">",
"      Silver nitrate: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/46/20194?source=related_link\">",
"      Silver nitrate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_53_42835="Consequences of treatment delay for breast abscess";
var content_f41_53_42835=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F62468&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F62468&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Consequences of treatment delay for breast abscess",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 363px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Breast abscess where there was a delay (A) at diagnosis and (B) poor cosmetic outcome due to delay in treatment.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael J Dixon, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_53_42835=[""].join("\n");
var outline_f41_53_42835=null;
var title_f41_53_42836="Hyperacute or peaked T waves";
var content_f41_53_42836=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F60464&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F60464&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 520px\">",
"   <div class=\"ttl\">",
"    Hyperacute (peaked) T waves",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 500px; height: 131px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hyperacute T waves are &gt;5 mm in the limb leads, and usually &gt;10 mm in the precordial leads. They have a peaked, symmetric morphology.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_53_42836=[""].join("\n");
var outline_f41_53_42836=null;
var title_f41_53_42837="Acitretin: Patient drug information";
var content_f41_53_42837=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Acitretin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/1/39958?source=see_link\">",
"     see \"Acitretin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F130260\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Soriatane&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F130261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Soriatane&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10026751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Women: Do not take this drug if you are pregnant or want to get pregnant in the next 3 years. Your doctor will talk with you about the chance of pregnancy before starting you on this drug. Use 2 helpful kinds of birth control 1 month before starting this drug and for 3 years after care ends. Pregnancy tests will be done to show that you are NOT pregnant before starting and while taking this drug. If you get pregnant while taking this drug, call your doctor right away. If you know all the facts and can follow how to take this drug, you must sign a patient fact/consent form. Do not sign the form and do not take this drug if you do not know everything on the form.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700245",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Women: Do not drink beer, wine, or mixed drinks while using this drug and for 2 months after stopping it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700244",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not donate blood while using this drug and for 3 years after stopping.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700734",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause liver problems. Call your doctor if you see dark urine, feel tired, are not hungry, have an upset stomach, are throwing up, or have yellowing of the skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10026753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat psoriasis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10026752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701435",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to acitretin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701044",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink beer, wine, or mixed drinks or take any drugs that have alcohol.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703620",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: High cholesterol, kidney disease, or liver disease.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701067",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are of childbearing age, but are not using 2 kinds of birth control or if you are planning to get pregnant during your care or within 3 years after care has ended.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10026757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696682",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid other sources of vitamin A.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696922",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use birth control pills that have a low dose of progesterone. They may not work well.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10026758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698143",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High cholesterol level.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698150",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High triglyceride level.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698243",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mouth irritation or sores. Using a soft toothbrush or cotton swabs and rinsing the mouth may help. Do not use mouth rinses that have alcohol in them.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nose irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698114",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hair loss. Hair most often grows back when this drug is stopped.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10026760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699114",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mean actions or thoughts of fighting.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698627",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699024",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699095",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling, warmth, or pain in the leg or arm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698963",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       More trips to the bathroom, more thirst, or weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698666",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, if you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10026755\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10026756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10026761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10026762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11161 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-202.43.93.2-77D3A94D3A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_53_42837=[""].join("\n");
var outline_f41_53_42837=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130260\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F130261\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026751\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026753\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026752\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026757\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026758\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026760\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026755\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026756\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026761\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026762\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?39/1/39958?source=related_link\">",
"      Acitretin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_53_42838="Overview of tibial fractures in children";
var content_f41_53_42838=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of tibial fractures in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/53/42838/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/53/42838/contributors\">",
"     Jennifer Chapman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/53/42838/contributors\">",
"     Joanna Cohen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/53/42838/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/53/42838/contributors\">",
"     Richard G Bachur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/53/42838/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/53/42838/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/53/42838/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tibial fractures are a common pediatric fracture. Young children and toddlers are at risk for tibial shaft fractures, even when the force of injury is low. The diagnosis should be suspected in all children with a limp or refusal to bear weight.",
"   </p>",
"   <p>",
"    Physical examination often allows localization of the fracture and should identify the presence of an open fracture or an acute compartment syndrome. Plain radiographs often suffice when assessing acute tibial injuries in children, but selected patients may require other forms of imaging. In patients with closed fractures and no sign of neurovascular compromise, initial management focuses on pain management, immobilization of the fracture, and reduction of swelling.",
"   </p>",
"   <p>",
"    An overview of tibial fractures in children is presented here. The evaluation and management of specific types of tibial fractures in children is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/51/42807?source=see_link\">",
"     \"Proximal tibial fractures in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/46/24296?source=see_link\">",
"     \"Tibial and fibular shaft fractures in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tibial fractures occur commonly in children. The mechanism of injury varies depending on the age of the patient. Low energy falls and twisting injuries account for most fractures in toddlers and younger children. High energy motor vehicle accidents and sports related injuries predominate in older children and adolescents (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef72158 \" href=\"mobipreview.htm?0/59/945\">",
"     image 1",
"    </a>",
"    ). The high energy transmitted to the soft tissues surrounding the bone is relevant because of the risk for compartment syndrome associated with tibial fractures. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Acute compartment syndrome'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Most tibial shaft fractures are short oblique or transverse fractures of the middle or distal third of the shaft [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42838/abstract/1\">",
"     1",
"    </a>",
"    ]. Tibial shaft fractures are associated with fibula fractures in 30 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42838/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Displaced fractures through the proximal tibial physis or metaphysis are relatively rare. With a significant hyperextension injury, posterior displacement of the proximal tibial shaft can disrupt the popliteal artery and cause distal ischemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42838/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Anatomy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tibia is the major weight-bearing bone of the lower leg (",
"    <a class=\"graphic graphic_picture graphicRef54800 \" href=\"mobipreview.htm?41/14/42213\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef65590 \" href=\"mobipreview.htm?26/45/27349\">",
"     picture 2",
"    </a>",
"    ). The tibial shaft bridges the tibial plateau, the proximal portion of the tibia forming the base of the knee joint, and the distal tibia, comprising the superior articular surface of the ankle joint at the tibiotalar articulation and the medial malleolus.",
"   </p>",
"   <p>",
"    The tibial tuberosity is a key landmark that is located one to two centimeters below the joint line and serves as the attachment site for the patellar tendon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42838/abstract/5\">",
"     5",
"    </a>",
"    ]. In active older children and young adolescents, it is subject to tensile forces that may lead to chronic inflammation and pain in this apophysis called Osgood-Schlatter disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/6/12392?source=see_link\">",
"     \"Osgood-Schlatter disease (tibial tuberosity avulsion)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In children, both the tibia and fibula consist of a long portion of bone (the diaphysis) with growth plates at either end (",
"    <a class=\"graphic graphic_figure graphicRef79444 \" href=\"mobipreview.htm?26/18/26918\">",
"     figure 1",
"    </a>",
"    ). The distal physes, particularly of the fibula, are areas vulnerable to fracture when subjected to inversion and eversion stresses. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/49/24345?source=see_link&amp;anchor=H26#H26\">",
"     \"Ankle fractures in children\", section on 'Distal fibula fractures'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A strong fibrous structure, the interosseous membrane connects the tibia and fibula along the length of the two bones. Proximally, this structure, reinforced by strong anterior and posterior ligaments, forms a synovial joint, the proximal tibiofibular articulation. Distally the interosseous membrane and three ligaments (the anterior, posterior, and transverse tibiofibular ligaments) stabilize the superior ankle joint.",
"   </p>",
"   <p>",
"    Another fibrous structure, the crural fascia, surrounds the bones and muscles of the lower leg. Fascial extensions and the interosseous membrane separate the muscles, nerves, and vessels of the lower leg into four distinct compartments (",
"    <a class=\"graphic graphic_figure graphicRef68629 \" href=\"mobipreview.htm?41/27/42424\">",
"     figure 2",
"    </a>",
"    ). Three of these (the anterior, posterior, and deep posterior compartments) border the tibia, but all of the compartments can be compromised by tibial injury.",
"   </p>",
"   <p>",
"    Nerves and vessels lie within the anterior and the deep posterior compartments, while the lateral compartment contains the superficial peroneal nerve (",
"    <a class=\"graphic graphic_picture graphicRef54800 \" href=\"mobipreview.htm?41/14/42213\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef65590 \" href=\"mobipreview.htm?26/45/27349\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef68629 \" href=\"mobipreview.htm?41/27/42424\">",
"     figure 2",
"    </a>",
"    ). Trauma that causes significant swelling in these compartments can result in neurovascular compromise. The key blood supply of the tibia arises from periosteal vessels and the nutrient artery. The nutrient artery originates from the posterior tibial artery and enters the posterolateral cortex at the middle third of the tibial shaft near the origin of the soleus muscle. Fractures in this region may compromise this blood supply.",
"   </p>",
"   <p>",
"    The periosteal vessels provide a less vulnerable circulation as they derive an abundant blood supply from the anterior tibial artery, which travels down along the interosseous membrane. Vascular compromise can arise more proximally from marked effusion of the knee joint or trauma that affects the popliteal artery before it branches into the anterior and posterior tibial arteries. Ischemia may also result from impingement of the anterior tibial artery as it branches off the popliteal artery and passes through a gap in the interosseous membrane (",
"    <a class=\"graphic graphic_picture graphicRef65590 \" href=\"mobipreview.htm?26/45/27349\">",
"     picture 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42838/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The tibial nerve and its branches (posterior tibial and common peroneal) provide the key innervation to the muscles of the lower leg and foot. Nerve roots arise from L4 through S3. The posterior tibial nerve parallels the course of the posterior tibial artery and courses through the deep posterior compartment. In the popliteal space, branches of the tibial nerve provide innervation to the posterior compartment and to the popliteus muscle. The common peroneal nerve divides into deep and superficial branches as it courses around the fibular neck. The deep peroneal nerve branches and follows the course of the anterior tibial artery providing innervation to muscles in the anterior lower leg. The superficial peroneal nerve is purely sensory and supplies sensation to the dorsum of the foot.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient with a suspected tibial fracture should undergo evaluation and management appropriate to the patient's mechanism of injury and physical findings. The clinician should evaluate unstable patients and those with a high risk trauma mechanism (",
"    <a class=\"graphic graphic_table graphicRef57293 \" href=\"mobipreview.htm?0/42/684\">",
"     table 1",
"    </a>",
"    ) according to the principles of advanced trauma life support (ATLS) (",
"    <a class=\"graphic graphic_figure graphicRef64241 \" href=\"mobipreview.htm?42/51/43834\">",
"     figure 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/16/29962?source=see_link\">",
"     \"Trauma management: Approach to the unstable child\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/11/40119?source=see_link\">",
"     \"Approach to the initially stable child with blunt or penetrating injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children with tibial fractures typically present with limp, pain, refusal to bear weight,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    deformity of the lower extremity. Sports injuries and motor vehicle collisions are common causes of injury in older children and adolescents.",
"   </p>",
"   <p>",
"    Isolated fractures of the tibia are common in toddlers and often result from low energy falls. However, the clinician should ensure that the mechanism of injury matches the severity of the fracture and perform a complete physical examination that searches for other physical signs of child abuse. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/54/26473?source=see_link\">",
"     \"Physical abuse in children: Epidemiology and clinical manifestations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/30/13802?source=see_link\">",
"     \"Orthopedic aspects of child abuse\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A complete evaluation of the entire lower extremity should be conducted before assuming that the injury is confined to the tibia, especially in a child who is less than five years of age",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    is nonverbal.",
"   </p>",
"   <p>",
"    Once other injuries are excluded, the examination can focus on the tibia. Analgesia prior to examination (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    10",
"    <span class=\"nowrap\">",
"     mg/kg;",
"    </span>",
"    maximum dose 800 mg for mild pain or intravenous",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/30/32233?source=see_link\">",
"     morphine",
"    </a>",
"    0.1 to 0.15",
"    <span class=\"nowrap\">",
"     mg/kg;",
"    </span>",
"    maximum single dose: 10 mg for moderate or severe pain) will often facilitate the child's cooperation. We suggest that the clinician avoid oral medications for patients likely to require sedation or general anesthesia for reduction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Inspection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians should inspect the injured lower leg for:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Swelling",
"     </li>",
"     <li>",
"      Deformity",
"     </li>",
"     <li>",
"      Lacerations or other open wounds suggesting an open fracture",
"     </li>",
"     <li>",
"      Tense swelling of the skin and muscles possibly indicating acute compartment syndrome",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The amount of swelling is not always a reliable guide to the presence of a tibial fracture, especially a toddler's fracture or stress fracture. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/46/24296?source=see_link\">",
"     \"Tibial and fibular shaft fractures in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with hyperextension injuries and suspicion for proximal tibial fractures are at greater risk for neurovascular compromise. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/51/42807?source=see_link\">",
"     \"Proximal tibial fractures in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Palpation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Palpation should include all of the bones of the leg, ankle, and foot. Clinicians should palpate the tibia looking for the point of maximal tenderness and assess the hip, knee, and ankle joints for swelling, tenderness, and the presence of effusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Neurovascular assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurovascular findings should be assessed in both legs.",
"   </p>",
"   <p>",
"    The clinician should palpate the posterior tibial and dorsalis pedis pulse and determine capillary refill in the foot.",
"   </p>",
"   <p>",
"    Sensory evaluation involves testing of the following nerves in the indicated sites:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Deep peroneal (fibular) nerve (between the first and second toes on the dorsum)",
"     </li>",
"     <li>",
"      Superficial peroneal (fibular) nerve (remainder of the dorsal foot)",
"     </li>",
"     <li>",
"      Medial plantar nerve (medial plantar surface from great toe to middle of the 4th toe)",
"     </li>",
"     <li>",
"      Lateral plantar nerve (lateral plantar surface from middle of the 4th toe to 5th toe)",
"     </li>",
"     <li>",
"      Sural nerve (lateral foot)",
"     </li>",
"     <li>",
"      Saphenous nerve (medial foot)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although pain may interfere with interpretation, the ability to extend and flex the toes tests the deep peroneal (fibular) and tibial nerves, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Acute compartment syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevated pressure due to increased volume within a constricting fascia can cause an acute compartment syndrome. Bleeding from a tibial fracture can extravasate into the posterior, deep posterior, or anterior compartment (",
"    <a class=\"graphic graphic_figure graphicRef68629 \" href=\"mobipreview.htm?41/27/42424\">",
"     figure 2",
"    </a>",
"    ) and elevate the intracompartmental pressure. Involvement of the lateral compartment usually suggests that a fibular injury is also present. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/57/8090?source=see_link\">",
"     \"Acute compartment syndrome of the extremities\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following findings suggest a developing compartment syndrome:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Excessive swelling and ecchymosis of the lower leg",
"     </li>",
"     <li>",
"      Increasing leg pain that is poorly responsive to parenteral analgesia",
"     </li>",
"     <li>",
"      Increased pain upon passive extension of the toes",
"     </li>",
"     <li>",
"      Tenseness of the affected muscle compartment",
"     </li>",
"     <li>",
"      Cold leg and foot with poor perfusion, pallor, and diminished or absent distal pulses (late findings)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinician should emergently consult an orthopedic surgeon for children with suspected acute compartment syndrome. Compartment pressure measurement typically helps guide further care. Fasciotomy constitutes definitive treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/57/8090?source=see_link&amp;anchor=H15#H15\">",
"     \"Acute compartment syndrome of the extremities\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plain radiographs typically suffice when assessing acute tibial injuries in children and include anterior-posterior (AP) and lateral views. These should incorporate the entire length of the lower leg from knee to ankle. Radiolucent splinting during the procedure reduces the risk of additional injury and allows proper positioning to best visualize fractures.",
"   </p>",
"   <p>",
"    Although the AP view is the best view for observing non-displaced spiral fractures commonly located in the distal tibia in toddlers (",
"    <a class=\"graphic graphic_picture graphicRef65590 \" href=\"mobipreview.htm?26/45/27349\">",
"     picture 2",
"    </a>",
"    ), oblique views of the tibia may aid in diagnosis when the AP and lateral plain radiographs are not revealing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42838/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/46/24296?source=see_link&amp;anchor=H7#H7\">",
"     \"Tibial and fibular shaft fractures in children\", section on 'Toddler's fractures'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Important features that can be assessed from the plain radiographs are the following (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/40/20104?source=see_link\">",
"     \"General principles of fracture management: Fracture patterns and description in children\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fracture location and type (eg, transverse, oblique, comminuted)",
"     </li>",
"     <li>",
"      Displacement",
"     </li>",
"     <li>",
"      Angulation",
"     </li>",
"     <li>",
"      Presence of growth plate fracture at the proximal",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      distal tibia (",
"      <a class=\"graphic graphic_figure graphicRef54582 \" href=\"mobipreview.htm?20/55/21361\">",
"       figure 4",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional imaging (eg, skeletal survey, computed tomography, bone scintigraphy, magnetic resonance imaging) may be warranted in selected patients. Possible indications include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nonreducible proximal tibial fracture (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/51/42807?source=see_link&amp;anchor=H6#H6\">",
"       \"Proximal tibial fractures in children\", section on 'Radiographic findings'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Suspected physical abuse (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/30/13802?source=see_link&amp;anchor=H6#H6\">",
"       \"Orthopedic aspects of child abuse\", section on 'Radiographic evaluation'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Febrile child with trauma and concern for bone infection (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/32/33289?source=see_link&amp;anchor=H6#H6\">",
"       \"Evaluation and diagnosis of hematogenous osteomyelitis in children\", section on 'Imaging'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Tibial stress fracture",
"     </li>",
"     <li>",
"      Distal tibial triplanar and Salter-Harris III or IV fractures (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/49/24345?source=see_link&amp;anchor=H19#H19\">",
"       \"Ankle fractures in children\", section on 'Computed tomography'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fractures of the proximal or distal growth plate are classified using the Salter-Harris system (",
"    <a class=\"graphic graphic_figure graphicRef54582 \" href=\"mobipreview.htm?20/55/21361\">",
"     figure 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/40/20104?source=see_link&amp;anchor=H15#H15\">",
"     \"General principles of fracture management: Fracture patterns and description in children\", section on 'Physeal fracture description'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/51/42807?source=see_link&amp;anchor=H14#H14\">",
"     \"Proximal tibial fractures in children\", section on 'Physeal fractures'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nonphyseal tibial injuries are classified according to location (proximal, midshaft, or distal). The treatment of tibial fractures by location is discussed in greater detail separately:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fractures of the proximal tibia (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/51/42807?source=see_link\">",
"       \"Proximal tibial fractures in children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Fractures of the tibial shaft (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/46/24296?source=see_link\">",
"       \"Tibial and fibular shaft fractures in children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Fractures of the distal tibial physis and malleolus (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/49/24345?source=see_link&amp;anchor=H27#H27\">",
"       \"Ankle fractures in children\", section on 'Distal tibia fractures'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     INITIAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The general principles of fracture management apply to tibial fractures. The approach to specific tibial fractures are presented separately in the appropriate topic reviews as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fractures of the proximal tibia (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/51/42807?source=see_link\">",
"       \"Proximal tibial fractures in children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Fractures of the tibial shaft (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/46/24296?source=see_link\">",
"       \"Tibial and fibular shaft fractures in children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Fractures of the distal tibial physis and malleolus (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/49/24345?source=see_link&amp;anchor=H27#H27\">",
"       \"Ankle fractures in children\", section on 'Distal tibia fractures'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Analgesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral analgesia (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?7/48/7946?source=see_link\">",
"     ibuprofen",
"    </a>",
"    10",
"    <span class=\"nowrap\">",
"     mg/kg;",
"    </span>",
"    maximum single dose 800 mg) may suffice for patients with mild pain who have suffered a nondisplaced tibial fracture, especially a toddler's fracture or buckle fracture. We suggest that the clinician avoid the oral route for patients likely to require sedation or general anesthesia for fracture reduction or repair.",
"   </p>",
"   <p>",
"    Opioid analgesia (eg, intravenous",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?31/30/32233?source=see_link\">",
"     morphine",
"    </a>",
"    0.1 to 0.15",
"    <span class=\"nowrap\">",
"     mg/kg;",
"    </span>",
"    maximum single dose: 10 mg) is most appropriate for initial pain control in patients with moderate to severe pain and should be given prior to radiographic evaluation. Persistent pain despite adequate parenteral opioid administration should prompt the clinician to evaluate the patient carefully for a developing acute compartment syndrome. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Acute compartment syndrome'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/15/44280?source=see_link&amp;anchor=H16#H16\">",
"     \"Evaluation and management of pain in children\", section on 'Opioids'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Splinting",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician should minimize further tissue injury, particularly of neural and vascular structures, by immobilizing the fracture. Because substantial soft tissue swelling can occur, initial immobilization is generally achieved by applying a removable plaster or fiberglass long leg splint. The splint should extend from the metatarsal heads to the proximal thigh just distal to the hip. The clinician should ensure extensive padding around the proximal fibular neck and head to avoid compression of the peroneal nerves and at the heel to avoid skin breakdown. The splint will later be removed to allow for reduction, fixation, or replacement with a better fitting cast.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Reduction of swelling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients without signs of acute compartment syndrome should have the lower leg elevated above the level of the heart and undergo cold application to minimize swelling. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Acute compartment syndrome'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Further management of tibial fractures varies with the anatomic location of the fracture. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/51/42807?source=see_link\">",
"     \"Proximal tibial fractures in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/46/24296?source=see_link\">",
"     \"Tibial and fibular shaft fractures in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/51/11058?source=see_link\">",
"       \"Patient information: Cast and splint care (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?25/21/25937?source=see_link\">",
"       \"Patient information: Cast and splint care (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tibia is the major weight-bearing bone of the lower leg (",
"    <a class=\"graphic graphic_picture graphicRef54800 \" href=\"mobipreview.htm?41/14/42213\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef65590 \" href=\"mobipreview.htm?26/45/27349\">",
"     picture 2",
"    </a>",
"    ). In children, both the tibia and fibula consist of a long portion of bone (the diaphysis) with growth plates at either end (",
"    <a class=\"graphic graphic_figure graphicRef79444 \" href=\"mobipreview.htm?26/18/26918\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Anatomy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Clinical findings",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children with tibial fractures typically present with limp, pain, refusal to bear weight,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      deformity of the lower extremity. Sports injuries and motor vehicle collisions are common mechanisms of injury in older children and adolescents (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef72158 \" href=\"mobipreview.htm?0/59/945\">",
"       image 1",
"      </a>",
"      ). Low energy falls and twisting injuries account for most fractures in toddlers and younger children. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinician should conduct a complete physical examination with special attention to findings that may suggest multiple trauma, open fracture, acute compartment syndrome,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      child abuse. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Plain radiographs typically suffice when assessing acute tibial injuries in children and include anterior-posterior (AP) and lateral views. These should incorporate the entire length of the lower leg from knee to ankle. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fractures of the proximal or distal growth plate are classified using the Salter-Harris system (",
"      <a class=\"graphic graphic_figure graphicRef54582 \" href=\"mobipreview.htm?20/55/21361\">",
"       figure 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Classification'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/40/20104?source=see_link&amp;anchor=H15#H15\">",
"       \"General principles of fracture management: Fracture patterns and description in children\", section on 'Physeal fracture description'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Nonphyseal tibial injuries are classified according to location (proximal, midshaft, or distal). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with closed fractures and no sign of neurovascular compromise, initial management focuses on pain management, immobilization of the fracture, and reduction of swelling. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Initial management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of tibial fractures by location are discussed in greater detail separately:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Fractures of the proximal tibial (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/51/42807?source=see_link\">",
"       \"Proximal tibial fractures in children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Fractures of the tibial shaft (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/46/24296?source=see_link\">",
"       \"Tibial and fibular shaft fractures in children\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Fractures of the distal tibial physis and malleolus (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/49/24345?source=see_link&amp;anchor=H27#H27\">",
"       \"Ankle fractures in children\", section on 'Distal tibia fractures'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42838/abstract/1\">",
"      Yang JP, Letts RM. Isolated fractures of the tibia with intact fibula in children: a review of 95 patients. J Pediatr Orthop 1997; 17:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42838/abstract/2\">",
"      Mashru RP, Herman MJ, Pizzutillo PD. Tibial shaft fractures in children and adolescents. J Am Acad Orthop Surg 2005; 13:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42838/abstract/3\">",
"      Wozasek GE, Moser KD, Haller H, Capousek M. Trauma involving the proximal tibial epiphysis. Arch Orthop Trauma Surg 1991; 110:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42838/abstract/4\">",
"      Shelton WR, Canale ST. Fractures of the tibia through the proximal tibial epiphyseal cartilage. J Bone Joint Surg Am 1979; 61:167.",
"     </a>",
"    </li>",
"    <li>",
"     Heinrich SD, Mooney JF. Fractures of the shaft of the tibia and fibular. In: Rockwood and Wilkins' Fractures in Children, 4th, Wilkins KE, Beaty JH.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.1033.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42838/abstract/6\">",
"      Tenenbein M, Reed MH, Black GB. The toddler's fracture revisited. Am J Emerg Med 1990; 8:208.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6551 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-222.190.118.195-3C09538E6E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_53_42838=[""].join("\n");
var outline_f41_53_42838=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Inspection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Palpation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Neurovascular assessment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Acute compartment syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      INITIAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Analgesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Splinting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Reduction of swelling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Clinical findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6551\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6551|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?0/59/945\" title=\"diagnostic image 1\">",
"      Distal tibia fibula fracture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6551|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?26/18/26918\" title=\"figure 1\">",
"      Growth plate anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?41/27/42424\" title=\"figure 2\">",
"      Muscle compartments of the leg",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?42/51/43834\" title=\"figure 3\">",
"      Initial trauma management in the severely injured child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?20/55/21361\" title=\"figure 4\">",
"      Salter-Harris classification system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6551|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?41/14/42213\" title=\"picture 1\">",
"      Anterior anatomy of tibia and fibula",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?26/45/27349\" title=\"picture 2\">",
"      Lateral anatomy of tibia and fibula",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6551|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?0/42/684\" title=\"table 1\">",
"      High risk trauma mechanisms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/57/8090?source=related_link\">",
"      Acute compartment syndrome of the extremities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/49/24345?source=related_link\">",
"      Ankle fractures in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/11/40119?source=related_link\">",
"      Approach to the initially stable child with blunt or penetrating injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/32/33289?source=related_link\">",
"      Evaluation and diagnosis of hematogenous osteomyelitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/15/44280?source=related_link\">",
"      Evaluation and management of pain in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/40/20104?source=related_link\">",
"      General principles of fracture management: Fracture patterns and description in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/30/13802?source=related_link\">",
"      Orthopedic aspects of child abuse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/6/12392?source=related_link\">",
"      Osgood-Schlatter disease (tibial tuberosity avulsion)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?25/21/25937?source=related_link\">",
"      Patient information: Cast and splint care (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/51/11058?source=related_link\">",
"      Patient information: Cast and splint care (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/54/26473?source=related_link\">",
"      Physical abuse in children: Epidemiology and clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/51/42807?source=related_link\">",
"      Proximal tibial fractures in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/46/24296?source=related_link\">",
"      Tibial and fibular shaft fractures in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/16/29962?source=related_link\">",
"      Trauma management: Approach to the unstable child",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_53_42839="Guanfacine: Pediatric drug information";
var content_f41_53_42839=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Guanfacine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?31/17/32023?source=see_link\">",
"    see \"Guanfacine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?1/32/1541?source=see_link\">",
"    see \"Guanfacine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F178166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Intuniv&reg;;",
"     </li>",
"     <li>",
"      Tenex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1017394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Alpha",
"       <sub>",
"        2",
"       </sub>",
"       -Adrenergic Agonist",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1017415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?31/17/32023?source=see_link\">",
"      see \"Guanfacine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Immediate release and extended release products should not be interchanged on a mg-per-mg basis due to differences in pharmacokinetic profiles.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      ADHD:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Immediate release product: Limited data available [Pliszka, 2007 (AACAP Practice Parameters)]: Children &ge;6 years and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     &le;45 kg: Oral: Initial: 0.5 mg once daily at bedtime; may titrate every 3-4 days in 0.5 mg/day  increments to 0.5 mg twice daily, then 0.5 mg three times daily, then 0.5 mg four times daily; maximum daily dose: Patient weight 27-40.5 kg: 2 mg/",
"     <b>",
"      day",
"     </b>",
"     ; 40.5-45 kg: 3 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     &gt;45 kg: Oral: Initial: 1 mg once daily at bedtime; may titrate every 3-4 days in 1 mg/day increments to 1 mg twice daily, then 1 mg three times daily, then 1 mg four times daily; maximum daily dose: 4 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Extended release product (Intuniv&reg;): Children and Adolescents 6-17 years: Oral: Initial: 1 mg once daily administered in the morning; may titrate dose  by no more than 1 mg/week increments, as tolerated. Usual maintenance dose: 1-4 mg/day; maximum daily dose: 4 mg/",
"     <b>",
"      day",
"     </b>",
"     . If patient misses two or more consecutive doses, repeat titration of dose should be considered. In clinical monotherapy trials, initial clinical response was associated with doses of 0.05-0.08 mg/kg once daily; increased efficacy was seen with increasing mg/kg doses; doses up to 0.12 mg/kg once daily have shown benefit when tolerated. In adjunctive therapy trials with stimulant medication, doses of 0.05-0.12 mg/kg/day produced optimal clinical response in the majority of patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Conversion from immediate release guanfacine to the extended release product: Discontinue the immediate release product; initiate the extended release product at the doses recommended above.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Discontinuation of therapy: Taper dose by no more than 1 mg every 3-7 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children &ge;12 years and Adolescents: Immediate release product: Oral: 1 mg usually at bedtime; may increase, if needed, at 3- to 4-week intervals; usual range: 0.5-2 mg/day; maximum daily dose: 2 mg/",
"     <b>",
"      day",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Pervasive  developmental disorders (PDD) and ADHD:",
"     </b>",
"     Limited data available; efficacy results variable: Children and Adolescents 5-14 years: Immediate release product:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &lt;25 kg: Oral: Initial: 0.25 mg once daily, increase dose as tolerated every 4 days in 0.25 mg/day increments in 2-3 divided doses; maximum daily dose: 3 mg/",
"     <b>",
"      day",
"     </b>",
"     (Scahill, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &ge;25 kg: Oral: Initial: 0.5 mg once daily, increase dose as tolerated every 4 days in 0.5 mg/day increments in 2-3 divided doses; maximum daily dose: 3 mg/",
"     <b>",
"      day",
"     </b>",
"     (Handen, 2008; Scahill, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Dosing based on a double-blind, placebo-controlled, 6-week crossover trial conducted in children with ADHD and autism or intellectual disabilities (n=11; age: 5-9 years);  five of 11 patients showed improvement in hyperactivity scores; other patient assessment parameters did not show improvements (Handen, 2008). In an open-label 8-week pilot study in children with ADHD and PDD (n=25; mean age: 9 years; range: 5-14 years), patients showed improvement in parent- and teacher-rated hyperactivity subscale scores; increased irritability occurred in seven patients; the authors note that patients with PDD may be more sensitive to irritability-type adverse effects (Scahill, 2006). A retrospective chart review of pediatric autism spectrum disorders (n=80; age: 3-18 years) reported ~24% of patients responded to mean dose of 2.6 mg/day; the authors noted patients with Asperger&rsquo;s or PDD not otherwise specified (NOS) responded more frequently than those with autistic disorder or comorbidity of mental retardation (Posey, 2004). Further studies are needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Tic disorder and ADHD:",
"     </b>",
"     Limited data available: Children and Adolescents 7-16 years: Immediate release product:Oral: Initial: 0.5 mg once daily at bedtime for 3 days, then 0.5 mg twice daily for 4 days, then 0.5 mg 3 times daily for 7 days; further upward titration based on clinical response; dosing based on a double-blind, placebo-controlled study in patients with ADHD and mild to moderate tics (n=34; mean age: 10.4 years; range: 7-14 years); reported final dose range: 1.5-3 mg/day in 3 divided doses; improvement in teacher-rated ADHD scores and tic scores after 8 weeks was reported (Scahill, 2001). A small open-label trial (n=10; age range: 8-16 years) used similar initial doses with dose titration; final dose range: 0.75-3 mg/day in divided doses; 7 of 10 patients required a final dose of 1.5 mg/day in divided doses (Chappell, 1995). Further studies are needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"     <b>",
"      Hypertension:",
"     </b>",
"     Immediate release: Oral: 1 mg usually at bedtime; may increase, if needed, at 3- to 4-week intervals; usual dose range (JNC 7): 0.5-2 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     No specific dosage adjustments are recommended by the manufacturer; use low end of the dosing range; consider dosage reduction in patients with clinically significant renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     No specific dosage adjustments are recommended by the manufacturer; consider dosage reduction in patients with clinically significant hepatic impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F178152\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 1 mg, 2 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tenex&reg;: 1 mg, 2 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intuniv&reg;: 1 mg, 2 mg, 3 mg, 4 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F178139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes extended release tablet",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10105744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Extended release: Swallow tablet whole with water, milk, or other liquid; do not crush, break, or chew; do not administer with high-fat meal.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10105659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immediate release: Store at room temperature between 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Dispense in tightly closed, light-resistant container.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Extended release: Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1017395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immediate release: Management of hypertension (FDA approved ages &ge;12 years and adults); has also been used in attention-deficit/hyperactivity disorder (ADHD), including ADHD with tic disorder (or Tourette's syndrome) and ADHD with autism or pervasive developmental disorders (PDD) comorbidities",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Extended release: Short-term treatment (&le;9 weeks) of ADHD as monotherapy or adjunctive therapy with stimulant medication (FDA approved in ages 6-17 years); has also been used for long-term treatment (24 months) of ADHD (Biederman, 2008; Sallee, 2009)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F178195\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       GuanFACINE may be confused with guaiFENesin, guanabenz, guanidine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Tenex&reg; may be confused with Entex&reg;, Xanax&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - low; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Tenex [U.S., Canada] may be confused with Kinex brand name for biperiden [Mexico]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F178194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: AV block, bradycardia, chest pain, hyper-/hypotension, orthostasis, pallor, sinus arrhythmia, syncope",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, fatigue, fever (Biederman, 2008), headache, insomnia, irritability, lethargy, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, appetite decreased, constipation, diarrhea, dyspepsia, nausea, stomach discomfort, vomiting, weight gain, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Enuresis, impotence, urinary frequency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: ALT increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Asthma",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Alopecia, amnesia, depression, dermatitis, dysphagia, edema, exfoliative dermatitis, hypersensitivity reaction, hypokinesia, iritis, nocturia, palpitation, paresis, rebound hypertension, seizure, tachycardia, urinary incontinence, vision disturbance",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1017397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to guanfacine or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10105656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with renal or hepatic impairment; dose reduction may be required if impairment is clinically significant. Use with caution in patients with a history of hypotension, heart block, bradycardia, cardiovascular disease, severe coronary insufficiency, recent MI, cerebrovascular disease, syncope, or a condition that predisposes patient to syncope. Use with caution with other agents that may reduce blood pressure or heart rate or increase risk of syncope. May cause drowsiness, sedation, and somnolence; use with caution with other agents that may cause CNS depression (eg, phenothiazines, barbituates, benzodiazepines). Warn patient of possible impairment of alertness or physical coordination and to avoid alcohol.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1017398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause bradycardia, hypotension, orthostatic hypotension, and syncope; these effects may be more pronounced during the first month of therapy. Modest, dose-dependent decreases in blood pressure and heart rate (typically asymptomatic) have also been reported. Do not abruptly discontinue; abrupt discontinuation can result in nervousness, anxiety, and rebound hypertension; dose should be tapered by no more than 1 mg every 3-7 days.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The American Heart Association recommends that all children diagnosed with ADHD who may be candidates for medication, such as guanfacine, should have a thorough cardiovascular assessment prior to initiation of therapy. These recommendations are based upon reports of serious cardiovascular adverse events (including sudden death) in patients (both children and adults) taking usual doses of stimulant medications. Most of these patients were found to have underlying structural heart disease (eg, hypertrophic obstructive cardiomyopathy). This assessment should include a combination of thorough medical history, family history, and physical examination. An ECG is not mandatory but should be considered.",
"     <b>",
"      Note:",
"     </b>",
"     In older clinical data, ECG abnormalities and four cases of sudden cardiac death were reported in children receiving clonidine (a less selective alpha",
"     <sub>",
"      2",
"     </sub>",
"     -agonist) with methylphenidate; reduce dose of methylphenidate by 40% when used concurrently with clonidine; consider ECG monitoring. However, more recent (published after 2001) multicenter trials have not reported serious cardiovascular outcomes or events in medically screened children and adolescents receiving concomitant clonidine and psychostimulant therapy; the most frequent reported adverse effects with combination therapy  were drowsiness, dizziness, and somnolence (Wilens, 2012). A double-blind, placebo-controlled trial of 461 pediatric patients (age: 6-17 years) examining the effect of the addition of extended release guanfacine to current psychostimulant therapy did not report any cardiovascular adverse events; in this trial, the most common (&gt;10% incidence) treatment emergent adverse effects were headache, somnolence, fatigue, and dizziness (Wilens, 2012). Further studies are needed to examine the long-term safety and efficacy of guanfacine in combination with psychostimulants.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Several cases of skin rash with exfoliation have been reported; however, a clear causal relationship could not be established. Discontinue guanfacine and monitor patients who develop a rash. Formulations of guanfacine (immediate release vs extended release) are not interchangeable on a mg-per-mg basis (due to differences in bioavailability).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9837647\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F178147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Alpha2-Antagonist): May diminish the antihypertensive effect of Alpha2-Agonists. Management: Consider avoiding concurrent use.  If these combinations cannot be avoided, monitor for decreased effects of alpha2-agonists if an alpha2-antagonist is initiated/dose increased, or increased effects if an alpha2-antagonist is discontinued/dose decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Alpha2-Agonists may enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the alpha",
"     <sub>",
"      2",
"     </sub>",
"     -agonist is abruptly withdrawn.  Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May decrease the serum concentration of GuanFACINE. Management: Consider increasing the guanfacine dose by 2-fold when adding a strong CYP3A4 inducer.  Titrate the guanfacine dose up to a max of 8 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase the serum concentration of GuanFACINE. Management: Reduce the guanfacine dose by 50% when adding a strong CYP3A4 inhibitor.  Limit the guanfacine dose to 2 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: GuanFACINE may increase the serum concentration of Divalproex.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Alpha2-Agonists may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: May diminish the antihypertensive effect of Alpha2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May decrease the serum concentration of GuanFACINE. Management: Consider increasing the guanfacine dose by 2-fold when adding St Johns Wort.  Titrate the guanfacine dose up to a max of 8 mg/day when starting guanfacine in a patient who is taking St Johns Wort.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May diminish the antihypertensive effect of Alpha2-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: GuanFACINE may increase the serum concentration of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F10105658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Extended release formulation:  A high-fat meal increases peak concentration by 75% and AUC by 40% compared to the fasted state",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F178148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9612487\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies indicate decreased fetal survival when administered at higher doses than recommended in humans. There are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if the benefits justify the risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F10268673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Heart rate, blood pressure, consider ECG monitoring in patients with history of heart disease or concurrent use of medications affecting cardiac conduction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     ADHD: Evaluate patients for cardiac disease prior to initiation of therapy for ADHD with thorough medical history, family history, and physical exam; consider ECG; perform ECG and echocardiogram if findings suggest cardiac disease; promptly conduct cardiac evaluation in patients who develop chest pain, unexplained syncope, or any other symptom of cardiac disease during treatment.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1017409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Selectively stimulates alpha",
"     <sub>",
"      2A",
"     </sub>",
"     -adrenoreceptors in the brain stem, thus activating an inhibitory neuron, resulting in reduced sympathetic outflow, producing a decrease in vasomotor tone and heart rate. The exact mechanism in ADHD is not known. It has been proposed that postsynaptic alpha",
"     <sub>",
"      2A",
"     </sub>",
"     -agonist stimulation regulates subcortical activity in the prefrontal cortex, the area of the brain responsible for emotions, attentions, and behaviors and causes reduced hyperactivity, impulsiveness, and distractibility. Guanfacine also acutely stimulates the release of growth hormone; however, with long-term use, it has no effect on growth hormone serum concentrations.",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F10268351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Antihypertensive effect: Duration: 24 hours following single dose",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1017410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     When dosed at same mg dose, the extended-release product has a lower peak serum concentration (60% lower) and AUC (43% lower) compared to the immediate release formulation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release: V",
"     <sub>",
"      d",
"     </sub>",
"     : 6.3 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended release: V",
"     <sub>",
"      d",
"     </sub>",
"     (apparent): Children: 23.7 L/kg; Adolescent: 19.9 L/kg (Boellner, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~70%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism:  Hepatic via CYP3A4",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release: ~80%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended release (relative to immediate release): 58%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release: ~17 hours (range: 10-30 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended release: Children: 14.4 hours; Adolescents: 18 hours (Boellner, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release: 2.6 hours (range: 1-4 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended release: Children and Adolescents: 5 hours (Boellner, 2007); Adults: 4-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: ~50% (40% to 75% of dose) excreted as unchanged drug in urine; tubular secretion of the drug may occur",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Not dialyzable in clinically significant amounts (2.4%)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1017419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?1/32/1541?source=see_link\">",
"      see \"Guanfacine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid alcohol; may cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; do not stop drug abruptly; may cause dry mouth; avoid becoming dehydrated or overheated. Do not take Intuniv&reg; with other guanfacine-containing medications (eg, Tenex&reg;).",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1017420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Guanfacine is a more selective alpha",
"     <sub>",
"      2",
"     </sub>",
"     -agonist than clonidine; withdrawal effects less commonly occur due to its longer half-life.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Medications used to treat ADHD should be part of a total treatment program that may include other components, such as psychological, educational, and social measures. Long-term usefulness of guanfacine for the treatment of ADHD should be periodically re-evaluated in patients receiving the drug for extended periods of time.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics/American Heart Association Clarification of Statement on Cardiovascular Evaluation and Monitoring of Children and Adolescents With Heart Disease Receiving Medications for ADHD; available at: file://americanheart.mediaroom.com/index.php?s=43&amp;item=422.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Biederman J, Melmed RD, Patel A, et al, &ldquo;A Randomized, Double-Blind, Placebo-Controlled Study of Guanfacine Extended Release in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 121(1):e73-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/53/42839/abstract-text/18166547/pubmed\" id=\"18166547\" target=\"_blank\">",
"        18166547",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Biederman J, Melmed RD, Patel A, et al, \"Long-Term, Open-Label Extension Study of Guanfacine Extended Release in Children and Adolescents With ADHD,\"",
"      <i>",
"       CNS Spectr",
"      </i>",
"      , 2008, 13(12):1047-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/53/42839/abstract-text/19179940/pubmed\" id=\"19179940\" target=\"_blank\">",
"        19179940",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boellner SW, Pennick M, Fiske K, et al, \"Pharmacokinetics of a Guanfacine Extended-Release Formulation in Children and Adolescents With Attention-Deficit-Hyperactivity Disorder,\"",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2007, 27(9):1253-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/53/42839/abstract-text/17723079/pubmed\" id=\"17723079\" target=\"_blank\">",
"        17723079",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chappell PB, Riddle MA, Scahill L, et al, \"Guanfacine Treatment of Comorbid Attention-Deficit Hyperactivity Disorder and Tourette's Syndrome: Preliminary Clinical Experience,\"",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 1995, 34(9):1140-6.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dopheide JA and Pliszka SR, \"Attention-Deficit-Hyperactivity Disorder: An Update,\"",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2009, 29(6):656-79.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/53/42839/abstract-text/19476419/pubmed\" id=\"19476419\" target=\"_blank\">",
"        19476419",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Handen BL, Sahl R, and Hardan AY, \"Guanfacine in Children With Autism and/or Intellectual Disabilities,\"",
"      <i>",
"       J Dev Behav Pediatr",
"      </i>",
"      , 2008, 29(4):303-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/53/42839/abstract-text/18552703/pubmed\" id=\"18552703\" target=\"_blank\">",
"        18552703",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pliszka S and AACAP Work Group on Quality Issues, \"Practice Parameter for the Assessment and Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder,\"",
"      <i>",
"       Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 2007, 46(7):894-921.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/53/42839/abstract-text/17581453/pubmed\" id=\"17581453\" target=\"_blank\">",
"        17581453",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Posey DJ, Puntney JI, Sasher TM, et al, \"Guanfacine Treatment of Hyperactivity and Inattention in Pervasive Developmental Disorders: A Retrospective Analysis of 80 Cases,\"",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 2004, 14(2):233-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/53/42839/abstract-text/15319020/pubmed\" id=\"15319020\" target=\"_blank\">",
"        15319020",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sallee FR, Lyne A, Wigal T, et al, &ldquo;Long-Term Safety and Efficacy of Guanfacine Extended Release in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder,&rdquo;",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 2009, 19(3):215-26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/53/42839/abstract-text/19519256/pubmed\" id=\"19519256\" target=\"_blank\">",
"        19519256",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sallee FR, McGough J, Wigal T, et al, &ldquo;Guanfacine Extended Release in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: A Placebo-Controlled Trial,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 2009, 48(2):155-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/53/42839/abstract-text/19106767/pubmed\" id=\"19106767\" target=\"_blank\">",
"        19106767",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Scahill L, Aman MG, McDougle CJ, et al, \"A Prospective Open Trial of Guanfacine in Children With Pervasive Developmental Disorders,\"",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 2006, 16(5):589-98.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/53/42839/abstract-text/17069547/pubmed\" id=\"17069547\" target=\"_blank\">",
"        17069547",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Scahill L, Chappell PB, Kim YS, et al, \"A Placebo-Controlled Study of Guanfacine in the Treatment of Children With Tic Disorders and Attention Deficit Hyperactivity Disorder,\"",
"      <i>",
"       Am J Psychiatry",
"      </i>",
"      , 2001, 158(7):1067-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/53/42839/abstract-text/11431228/pubmed\" id=\"11431228\" target=\"_blank\">",
"        11431228",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Scahill L, \"Alpha-2 Adrenergic Agonists in Attention Deficit Hyperactivity Disorder,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 2009, 154:S32-7.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Spencer TJ, Greenbaum M, Ginsberg LD, et al, \"Safety and Effectiveness of Coadministration of Guanfacine Extended Release and Psychostimulants in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder,\"",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 2009, 19(5):501-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/53/42839/abstract-text/19877974/pubmed\" id=\"19877974\" target=\"_blank\">",
"        19877974",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vetter VL, Elia J, Erickson C, et al, \"Cardiovascular Monitoring of Children and Adolescents With Heart Disease Receiving Medications for Attention Deficit/Hyperactivity Disorder [Corrected]: A Scientific Statement From the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2008, 117(18):2407-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/53/42839/abstract-text/18427125/pubmed\" id=\"18427125\" target=\"_blank\">",
"        18427125",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wilens TE, Bukstein O, Brams M, et al, \"A Controlled Trial of Extended-Release Guanfacine and Psychostimulants for Attention-Deficit/Hyperactivity Disorder,\"",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 2012, 51(1):74-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?41/53/42839/abstract-text/22176941/pubmed\" id=\"22176941\" target=\"_blank\">",
"        22176941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15555 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-708A4DD6E0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_53_42839=[""].join("\n");
var outline_f41_53_42839=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178166\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1017394\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1017415\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178152\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178139\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10105744\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10105659\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1017395\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178195\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178194\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1017397\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10105656\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1017398\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9837647\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178147\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10105658\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178148\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9612487\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10268673\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1017409\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10268351\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1017410\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1017419\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1017420\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15555\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15555|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?31/17/32023?source=related_link\">",
"      Guanfacine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?1/32/1541?source=related_link\">",
"      Guanfacine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_53_42840="Medical management of gastroesophageal reflux disease in adults";
var content_f41_53_42840=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Medical management of gastroesophageal reflux disease in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/53/42840/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/53/42840/contributors\">",
"     Peter J Kahrilas, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/53/42840/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/53/42840/contributors\">",
"     Nicholas J Talley, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/53/42840/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/53/42840/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/53/42840/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 19, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reflux esophagitis results from the combination of excessive gastroesophageal reflux of gastric juice and impaired esophageal clearance of the refluxate. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/38/13928?source=see_link\">",
"     \"Pathophysiology of reflux esophagitis\"",
"    </a>",
"    .) Although the relationship is imprecise, the likelihood of developing reflux symptoms or esophageal epithelial injury is a function of a quantitative abnormality of the number of reflux events",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    esophageal acid exposure. Hence, therapy should be titrated to disease severity.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mild symptomatic gastroesophageal reflux disease (GERD) can usually be managed empirically; lifestyle and dietary modifications along with antacids and nonprescription histamine-2 (H2) receptor antagonists are usually sufficient.",
"     </li>",
"     <li>",
"      Patients with debilitating symptoms usually require more pharmacologically sustained acid-suppressive therapy.",
"     </li>",
"     <li>",
"      Between these extremes, matching the potency of therapy with disease severity can be achieved either by a \"step up\" approach (beginning with lifestyle and dietary measures and incrementally increasing the therapeutic intervention over time until symptom control is achieved) or a \"step down\" approach (beginning with potent antisecretory agents to achieve rapid symptom control and then incrementally decreasing the intervention until break-through symptoms define the therapy necessary for continued adequate symptom control) (",
"      <a class=\"graphic graphic_table graphicRef72132 \" href=\"mobipreview.htm?4/33/4635\">",
"       table 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/53/42840/abstract/1,2\">",
"       1,2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When heartburn proves refractory to treatment, or is accompanied by dysphagia, odynophagia, or gastrointestinal bleeding, endoscopy should be done to detect other possible causes, such as eosinophilic esophagitis, infectious esophagitis, pill esophagitis, or malignancy. The components of the medical management of GERD will be reviewed here; the treatment of refractory disease, the role of surgery in this disorder, and the influence of Helicobacter pylori on GERD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/18/17706?source=see_link\">",
"     \"Approach to refractory gastroesophageal reflux disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/57/42905?source=see_link\">",
"     \"Surgical management of gastroesophageal reflux in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/46/9959?source=see_link\">",
"     \"Helicobacter pylori and gastroesophageal reflux disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     LIFESTYLE MODIFICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Minimal, but sensible, therapy for gastroesophageal reflux disease (GERD) patients is comprised of lifestyle modification, dietary modification, as needed antacid use, over-the-counter H2 receptor antagonists, and over-the-counter proton pump inhibitors. Lifestyle modifications are aimed at enhancing esophageal acid clearance, minimizing the incidence of reflux events, or both as with cessation of smoking and avoidance of late meals:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Head of bed elevation, which can be achieved either by putting 6- to 8-inch blocks under the legs at the head of the bed or a Styrofoam wedge under the mattress. Head of bed elevation is important for individuals with nocturnal or laryngeal symptoms; its necessity in other situations is questionable.",
"     </li>",
"     <li>",
"      Dietary modification may be helpful, but prohibition of many enjoyable foods virtually ensures noncompliance. It is more practical to suggest avoidance of a core group of reflux-inducing foods (fatty foods, chocolate, peppermint, and excessive alcohol, which may reduce lower esophageal sphincter pressure) and then to suggest that the patient selectively avoid foods known to cause symptoms. As an example, a number of beverages have a very acidic pH and can exacerbate symptoms. These include colas, red wine, and orange juice (pH 2.5 to 3.9).",
"     </li>",
"     <li>",
"      Refraining from assuming a supine position after meals and avoidance of meals two to three hours before bedtime, both of which will minimize reflux.",
"     </li>",
"     <li>",
"      Avoidance of tight fitting garments, which reduces reflux by decreasing the stress on a weak sphincter.",
"     </li>",
"     <li>",
"      Obesity is a risk factor for GERD, erosive esophagitis, and esophageal adenocarcinoma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/53/42840/abstract/3\">",
"       3",
"      </a>",
"      ]. However, improvement in symptoms following weight loss is not uniform [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/53/42840/abstract/4-8\">",
"       4-8",
"      </a>",
"      ]. Nevertheless, because of a possible benefit, and because of its other salutary effects, weight loss should be recommended.",
"     </li>",
"     <li>",
"      Promotion of salivation by either chewing gum or use of oral lozenges may also be helpful in mild heartburn. Salivation neutralizes refluxed acid, thereby increasing the rate of esophageal acid clearance.",
"     </li>",
"     <li>",
"      Restriction of alcohol use and elimination of smoking; smoking is deleterious in part because it diminishes salivation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although these approaches have been used clinically, their effectiveness has not been extensively evaluated in clinical trials. A systematic review of the published literature concluded that there was only evidence supporting the effectiveness of weight loss and head of bed elevation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42840/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Abdominal breathing exercises have been suggested as a way to improve GERD with the rationale of strengthening the anti-reflux barrier of the lower esophageal sphincter. This technique was examined in a randomized controlled trial with 19 patients with nonerosive GERD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42840/abstract/10\">",
"     10",
"    </a>",
"    ]. After four weeks, patients in the abdominal breathing group showed reduced esophageal acid exposure and improved quality of life scores compared with their baseline, whereas there were no changes among control patients. However, there were no significant differences in scores between the abdominal breathing group and the controls.",
"   </p>",
"   <p>",
"    At the end of four weeks, the control patients crossed over to abdominal breathing exercises. After nine months, those still performing the exercises (n = 11) had significant improvement in their quality of life scores and proton pump inhibitor usage compared with their baseline values, whereas those not performing the exercises showed no changes. Because the study was small and failed to show a difference between the patients assigned to abdominal breathing and the control patients, larger studies are required to confirm a benefit for this technique.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ACID SUPPRESSIVE MEDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acid suppressive medication regimens include, in increasing order of potency, over-the-counter antacids and H2 blockers at non-prescription strength, prescription strength H2 blockers, and proton pump inhibitors, administered as needed, once, or twice daily. In patients with mild to moderate GERD, symptom severity and previous treatments can guide the selection of an initial acid suppressive regimen (",
"    <a class=\"graphic graphic_table graphicRef72132 \" href=\"mobipreview.htm?4/33/4635\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef58448 \" href=\"mobipreview.htm?28/14/28897\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The most common and effective treatment of peptic esophagitis or symptomatic gastroesophageal reflux disease (GERD) is to reduce gastric acid secretion with either an H2 blocker or a proton pump inhibitor (PPI) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42840/abstract/11\">",
"     11",
"    </a>",
"    ]. The medication dose is titrated to the severity of disease for each patient, with the goal being to raise the intragastric pH above 4 during the periods of the day that reflux is likely to occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42840/abstract/12\">",
"     12",
"    </a>",
"    ]. The greater the degree of pathologic esophageal acid exposure, the greater the degree of acid suppression required. These therapies do not prevent reflux, but they reduce the acidity of the refluxate. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/38/13928?source=see_link\">",
"     \"Pathophysiology of reflux esophagitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many trials have established the efficacy of the various proton pump inhibitors and H2 antagonists in the treatment of esophagitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42840/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. However, unless the medications are compared head to head, ascertaining the",
"    <strong>",
"     relative",
"    </strong>",
"    efficacy of these drugs is complicated by the fact that esophagitis exists along a continuum of severity, and comparability of study populations among trials cannot be assumed.",
"   </p>",
"   <p>",
"    One way of indexing esophagitis severity among trials is by the placebo healing rate. The placebo healing rate is very low with severe esophagitis and relatively high in mild esophagitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42840/abstract/15\">",
"     15",
"    </a>",
"    ]. The H2 receptor antagonists offer a therapeutic gain of 10 to 24 percent relative to the placebo for healing esophagitis. However, the gain is nearly constant regardless of the placebo healing rate, indicating that these drugs are ineffective for severe esophagitis and do not exhibit a dose-response curve in the treatment of esophagitis. The different H2 receptor antagonist have equivalent efficacy if drug dose is adjusted for potency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42840/abstract/16\">",
"     16",
"    </a>",
"    ]. An increased dose or prolonged course of an H2 antagonist is unlikely to produce relief for patients who continue to have heartburn after six weeks of treatment with a standard dose of an H2 antagonist [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42840/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The proton pump inhibitors are more effective in healing esophagitis than the H2 receptor antagonists, with a therapeutic gain of 57 to 74 percent relative to placebo. In addition, proton pump inhibitors lead to more rapid healing and symptom relief than H2 receptor antagonists. In a meta-analysis, complete relief from heartburn occurred at a rate of 11.5 percent per week with a proton pump inhibitor compared to 6.4 percent per week with an H2 receptor antagonist [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42840/abstract/18\">",
"     18",
"    </a>",
"    ]. Furthermore, proton pump inhibitors exhibit a dose-response curve for healing high-grade esophagitis as evidenced by higher healing rates with higher doses",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    more potent compounds.",
"   </p>",
"   <p>",
"    A systematic review demonstrated that for treatment of regurgitation among patients with GERD, proton pump inhibitor (PPI) treatment was superior to placebo or an H2 receptor agonist. However, proton pump inhibitor treatment resulted in only a modest therapeutic gain in patients compared with placebo in those who reported the symptom at baseline (0 to 35 percent). This was similar to the therapeutic gain seen for proton pump inhibitor treatment over that with an H2 antagonist",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cisapride (5 to 38 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42840/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Nonerosive gastroesophageal reflux disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients with typical symptoms of GERD do not have esophagitis; such patients have been referred to as having nonerosive reflux disease (NERD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42840/abstract/20\">",
"     20",
"    </a>",
"    ]. Some of these patients have symptoms despite having normal levels of esophageal acid exposure as assessed by a 24-hour pH monitoring study. Such patients may have esophageal hypersensitivity to physiologic degrees of acid reflux. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/38/13928?source=see_link&amp;anchor=H13#H13\">",
"     \"Pathophysiology of reflux esophagitis\", section on 'Esophageal hypersensitivity'",
"    </a>",
"    .) Other NERD patients have abnormal acid exposure but have not developed overt mucosal injury. Still others have heartburn not attributable to acid reflux, sometimes referred to as \"functional heartburn\". The first two groups, but not the third group of patients, may respond to antisecretory therapy. At least three controlled trials and a meta-analysis suggest that proton pump inhibitors were associated with more effective symptom relief than placebo or H2 receptor antagonists in such patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42840/abstract/21-23\">",
"     21-23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Differences in proton pump inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have compared the various proton pump inhibitors to one another. While some differences have been reported, the magnitude of differences has been small and of uncertain clinical significance. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/28/25034?source=see_link\">",
"     \"Overview and comparison of the proton pump inhibitors for the treatment of acid-related disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ADJUNCTIVE THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1959668\">",
"    <span class=\"h2\">",
"     Prokinetic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prokinetic drugs (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/56/25476?source=see_link\">",
"     bethanechol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    ) increase lower esophageal sphincter pressure, enhance gastric emptying, and improve peristalsis. They may also reduce hiatus hernia size and therefore impact the position of the gastric acid pocket, which serves as a reservoir for acid reflux [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42840/abstract/24\">",
"     24",
"    </a>",
"    ]. However, it is unclear if treatment with prokinetics leads to a reduction in GERD symptoms. In addition, their use is limited by side effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42840/abstract/11\">",
"     11",
"    </a>",
"    ]. Consequently, there is currently no role for the use of prokinetics as monotherapy or adjunctive therapy for the treatment of GERD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1959675\">",
"    <span class=\"h2\">",
"     Reflux inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drugs that inhibit transient lower esophageal sphincter relaxation have also been considered for adjunctive treatment of GERD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42840/abstract/25\">",
"     25",
"    </a>",
"    ]. The gamma-aminobutyric type B receptors",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/31/36342?source=see_link\">",
"     baclofen",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42840/abstract/26-29\">",
"     26-29",
"    </a>",
"    ] and lesogaberan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42840/abstract/30\">",
"     30",
"    </a>",
"    ] have shown efficacy in decreasing reflux episodes in patients with GERD. Doses of baclofen used in these studies are higher than are typically used in the treatment of spasticity disorders. Baclofen, however, has not been used as a treatment option for GERD because of its adverse side effect profile (sedation, dizziness) at the doses that would be needed for effective treatment.",
"   </p>",
"   <p>",
"    In a double-blind, placebo-controlled, randomized phase IIA trial, treatment with lesogaberan, a novel gamma-aminobutyric type B receptor agonist, resulted in significantly improved heartburn and regurgitation symptoms compared to placebo; however, the proportion of responders was small (16 versus 8 percent). Lesogaberan was well tolerated with adverse events of mostly mild to moderate intensity that were comparable to the placebo group (45 versus 37 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42840/abstract/31\">",
"     31",
"    </a>",
"    ]. The role of lesogaberan as an add-on treatment in patients partially responding to PPIs has yet to be determined. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/38/13928?source=see_link\">",
"     \"Pathophysiology of reflux esophagitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     TREATMENT OF HELICOBACTER PYLORI INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A possible role for H. pylori in the pathogenesis of gastroesophageal reflux disease (GERD) has been suggested in a number of studies. However, the link between GERD and H. pylori is complex and incompletely defined. The main linkage is in the effect that H. pylori has on gastric acid secretion. Hence, eradication of H. pylori is associated with mild worsening of GERD in patients with pan-gastritis (hyposecretors) and improvement in those with antral-predominant gastritis (hypersecretors). These effects must be balanced against the risks of continued infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/46/9959?source=see_link\">",
"     \"Helicobacter pylori and gastroesophageal reflux disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MAINTENANCE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the propensity of esophagitis to relapse, maintenance acid suppressive therapy is often necessary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42840/abstract/32\">",
"     32",
"    </a>",
"    ]. However, a trial off medications should be considered in all patients with gastroesophageal reflux disease (GERD) who have a good clinical response to acid suppression with the exception of those with severe esophagitis on upper endoscopy (Los Angeles classification Grade C and D) and Barrett&rsquo;s esophagus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42840/abstract/33\">",
"     33",
"    </a>",
"    ]. Patients with severe esophagitis should remain on maintenance acid suppression as they are likely to have recurrent symptoms with discontinuation of acid suppression and are more likely to develop complications. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/41/22168?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical manifestations and diagnosis of gastroesophageal reflux in adults\", section on 'Los Angeles classification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The need for maintenance medical therapy is determined by the rapidity of recurrence. Recurrent symptoms in less than three months suggest disease best managed with continuous therapy, while recurrences occurring after more than three months can be managed by repeated courses of acute therapy as necessary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42840/abstract/34\">",
"     34",
"    </a>",
"    ]. Reducing the medication dose or attempting maintenance with a less potent agent than that used for healing often results in a high recurrence rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42840/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. The following conclusions were made in systematic reviews [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42840/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Proton pump inhibitors (PPIs) at a standard dose (as suggested by the manufacturer's prescribing information) or a lower dose (usually one-half of the standard dose) were more effective than H2RAs in resolving GERD symptoms at four weeks and promoting healing esophagitis at eight weeks.",
"     </li>",
"     <li>",
"      PPIs at a standard dose were more effective than a lower dose in preventing relapse of symptoms.",
"     </li>",
"     <li>",
"      PPIs at a standard dose were more effective than PPIs at a lower dose in maintaining healing of esophagitis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Intermittent therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intermittent (on-demand) therapy with an H2 receptor antagonist or proton pump inhibitor may be successful in some patients with mild to moderate heartburn without moderate-severe esophagitis. The optimal approach for prescribing intermittent therapy has not been established. One of the largest trials included 677 patients with mild to moderate heartburn and a normal endoscopy or only mild erosive changes were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    (10 or 20",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/56/42888?source=see_link\">",
"     ranitidine",
"    </a>",
"    (150 mg twice daily) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42840/abstract/39\">",
"     39",
"    </a>",
"    ]. After two weeks, asymptomatic patients were given no further therapy unless symptoms returned upon which they were treated for two to four weeks with the drug that initially caused remission. At the end of one year, approximately 50 percent of patients in all three treatment groups had not required medication for at least six months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59972519\">",
"    <span class=\"h2\">",
"     Safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;With maintenance antisecretory therapy being the rule rather than the exception, drug safety becomes an important issue. After a critical review of all available safety data, a 2008 guideline on gastroesophageal reflux disease (GERD) management developed by the American Gastroenterological Association Institute found insufficient evidence to recommend for or against bone density studies, calcium supplementation, H. pylori screening, or any other routine precaution in patients taking proton pump inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42840/abstract/11\">",
"     11",
"    </a>",
"    ]. However, studies subsequent to that guideline continue to raise concerns about possible infectious complications, electrolyte disturbances, and metabolic bone disease associated with PPI use. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/28/25034?source=see_link&amp;anchor=H59974871#H59974871\">",
"     \"Overview and comparison of the proton pump inhibitors for the treatment of acid-related disorders\", section on 'Safety'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H257926783\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR UPPER ENDOSCOPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The indications for upper endoscopy in patients with gastroesophageal reflux disease (GERD) are controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42840/abstract/33,40,41\">",
"     33,40,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We recommend an upper endoscopy if there is significant doubt about the diagnosis of GERD and in the following individuals:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Men and women with heartburn and alarm symptoms (dysphagia, bleeding, anemia, weight loss, and recurrent vomiting).",
"     </li>",
"     <li>",
"      Men and women with typical GERD symptoms that persist despite a therapeutic trial of four to eight weeks of twice-daily proton pump inhibitor therapy.",
"     </li>",
"     <li>",
"      Men older than 50 years with chronic GERD symptoms (symptoms for more than five years) and additional risk factors for Barrett&rsquo;s esophagus and esophageal adenocarcinoma (nocturnal reflux symptoms, hiatal hernia, elevated body mass index, tobacco use, and intra-abdominal distribution of fat).",
"     </li>",
"     <li>",
"      Severe erosive esophagitis after a two-month course of proton pump inhibitor therapy to assess healing and rule out Barrett's esophagus. Repeat endoscopy after this follow-up examination is not indicated in the absence of Barrett's esophagus unless patients have bleeding, dysphagia, or a significant change in symptoms while on effective therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These recommendations are largely consistent with the guidelines from the American College of Physicians [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42840/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/8/1161?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of Barrett's esophagus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/31/32250?source=see_link\">",
"     \"Epidemiology, pathobiology, and clinical manifestations of esophageal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The smooth muscle relaxation as well as the increased intraabdominal pressure that occur during pregnancy predisposes to gastroesophageal reflux [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42840/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/60/9160?source=see_link\">",
"     \"Maternal gastrointestinal tract adaptation to pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lifestyle modifications or antacids should be first-line therapy in symptomatic women. However, some patients are not controlled by these measures. The greatest experience with pharmacologic acid-suppressive therapy in pregnant women has been with the H2 receptor antagonists",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/56/42888?source=see_link\">",
"     ranitidine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/54/2921?source=see_link\">",
"     cimetidine",
"    </a>",
"    , which appear to be safe during pregnancy. The efficacy of ranitidine (150 mg PO twice daily) was demonstrated in a placebo-controlled, double-blind trial of 20 pregnant women whose heartburn was refractory to conservative measures; heartburn severity was reduced 44 percent compared to placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42840/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is less experience using proton pump inhibitors (PPIs) during pregnancy but they are probably safe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42840/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. A meta-analysis of seven studies (involving a total of 1530 exposed and 133,410 non-exposed pregnant women) found no significant difference in the risk for major congenital birth defects, spontaneous abortions, or preterm delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42840/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, 113 pregnant women exposed to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/62/26601?source=see_link\">",
"       omeprazole",
"      </a>",
"      during pregnancy were compared with controls exposed to known non teratogens and with women who took H2 blockers during pregnancy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/53/42840/abstract/46\">",
"       46",
"      </a>",
"      ]. Birth weight, gestational age at delivery, preterm deliveries, and neonatal complications were comparable among the three groups.",
"     </li>",
"     <li>",
"      A population-based case-control study involving 3236 births found that first trimester exposure to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/54/2921?source=see_link\">",
"       cimetidine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/62/26601?source=see_link\">",
"       omeprazole",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/56/42888?source=see_link\">",
"       ranitidine",
"      </a>",
"      was not associated with an increased risk of congenital malformations, preterm delivery, or growth retardation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/53/42840/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Similar conclusions were reached in another population-based study that found no increased risk of major teratogenic effects with exposure to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/62/26601?source=see_link\">",
"       omeprazole",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/14/3305?source=see_link\">",
"       lansoprazole",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/16/32009?source=see_link\">",
"       pantoprazole",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/53/42840/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a cohort study performed subsequent to the meta-analysis, there was no increase in the risk of major birth defects in 3651 infants exposed to PPIs during the first trimester compared with 837,317 infants who had not been exposed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/53/42840/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pregnancy ratings of the various PPIs (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/62/26601?source=see_link\">",
"     omeprazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/39/15993?source=see_link\">",
"     esomeprazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/14/3305?source=see_link\">",
"     lansoprazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/9/27799?source=see_link\">",
"     dexlansoprazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/16/32009?source=see_link\">",
"     pantoprazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/18/44327?source=see_link\">",
"     rabeprazole",
"    </a>",
"    ) are available in the drug formulary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/2/24610?source=see_link\">",
"       \"Patient information: Acid reflux (gastroesophageal reflux disease) in adults (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/31/19954?source=see_link\">",
"       \"Patient information: H. pylori infection (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/42/24226?source=see_link\">",
"       \"Patient information: Acid reflux (gastroesophageal reflux disease) during pregnancy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/30/38373?source=see_link\">",
"       \"Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/58/14242?source=see_link\">",
"       \"Patient information: Helicobacter pylori infection and treatment (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     MAJOR SOCIETY RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for the management of gastroesophageal reflux disease (GERD) have been proposed by a number of authorities and organizations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42840/abstract/11,33,49\">",
"     11,33,49",
"    </a>",
"    ]. The consensus recommendations were developed by the American Gastroenterological Association Institute and were based upon a systematic review and subsequent critique by a multidisciplinary consensus group (",
"    <a class=\"graphic graphic_table graphicRef51891 graphicRef64967 graphicRef76758 \" href=\"mobipreview.htm?27/31/28159\">",
"     table 2A-C",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42840/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many potential options for evaluating and treating patients with suspected gastroesophageal reflux disease (GERD). There is an abundance of data evaluating specific approaches in well-defined populations. What is less clear is the optimal care for GERD patients beginning with a suspected diagnosis and proceeding to a long-term maintenance strategy. Thus, our recommendations are based upon the strength of evidence for individual approaches and clinical experience (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    )&nbsp;(",
"    <a class=\"graphic graphic_algorithm graphicRef58448 \" href=\"mobipreview.htm?28/14/28897\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest lifestyle changes (eg, head of bed elevation, food avoidance before sleep, avoidance of foods that decrease lower esophageal sphincter [LES] pressures) in patients with GERD (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Lifestyle modifications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with worse than mild and intermittent GERD symptoms, we recommend acid suppressive therapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Acid suppressive medications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with GERD and moderate to severe esophagitis, we recommend acid suppression with a proton pump inhibitor (PPI) rather than a histamine-2 receptor antagonist (H2RA) (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Acid suppressive medications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest the stepwise use of therapies in patients with GERD according to the following algorithm (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We initiate therapy based mainly upon the patient's history including response to previous GERD therapy.",
"     </li>",
"     <li>",
"      Depending upon the initial therapy used, we adjust the medical regimen using a step-up or step-down approach with the goal of identifying the least potent, but still effective, regimen according to the scale of potency in the Table (",
"      <a class=\"graphic graphic_table graphicRef72132 \" href=\"mobipreview.htm?4/33/4635\">",
"       table 1",
"      </a>",
"      ). We consider the severity of persistent symptoms in guiding the approach. Patient comfort is optimized using a step-down approach, with incremental changes in therapy being made at two- to four-week intervals. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Acid suppressive medications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once identified, the optimal acute therapy should be maintained for at least eight weeks. Further evaluation should be undertaken if the most potent medical therapy still results in a poor symptomatic response (",
"      <a class=\"graphic graphic_algorithm graphicRef58448 \" href=\"mobipreview.htm?28/14/28897\">",
"       algorithm 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We recommend an upper endoscopy if there is significant doubt about the diagnosis and in the following individuals with GERD (see",
"      <a class=\"local\" href=\"#H257926783\">",
"       'Indications for upper endoscopy'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Men and women with heartburn and alarm symptoms (dysphagia, bleeding, anemia, weight loss, and recurrent vomiting).",
"     </li>",
"     <li>",
"      Men and women with typical GERD symptoms that persist despite a therapeutic trial of four to eight weeks of twice-daily proton pump inhibitor therapy.",
"     </li>",
"     <li>",
"      In men older than 50 years with chronic GERD symptoms (symptoms for more than five years) and additional risk factors (nocturnal reflux symptoms, hiatal hernia, elevated body mass index, tobacco use, and intra-abdominal distribution of fat) to detect esophageal adenocarcinoma and Barrett's esophagus.",
"     </li>",
"     <li>",
"      Severe erosive esophagitis after a two-month course of proton pump inhibitor therapy to assess healing and rule out Barrett's esophagus. Repeat endoscopy after this follow-up examination is not indicated in the absence of Barrett's esophagus unless patients have bleeding, dysphagia, or a significant change in symptoms while on effective therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A trial off medications should be considered in all patients with GERD who have a good clinical response to acid suppression with the exception of those with severe esophagitis on upper endoscopy (Los Angeles classification Grade C and D). The need for maintenance medical therapy is determined by the rapidity of recurrence. Recurrent symptoms in less than three months suggest disease best managed with continuous therapy, while recurrences occurring after more than three months can be managed by repeated courses of acute therapy as necessary. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Maintenance therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An approach to patient with \"refractory\" GERD is presented separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/18/17706?source=see_link\">",
"       \"Approach to refractory gastroesophageal reflux disease in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42840/abstract/1\">",
"      Inadomi JM, Jamal R, Murata GH, et al. Step-down management of gastroesophageal reflux disease. Gastroenterology 2001; 121:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42840/abstract/2\">",
"      Inadomi JM, McIntyre L, Bernard L, Fendrick AM. Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs. Am J Gastroenterol 2003; 98:1940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42840/abstract/3\">",
"      Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med 2005; 143:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42840/abstract/4\">",
"      Aslam M, Slaughter JC, Goutte M, et al. Nonlinear relationship between body mass index and esophageal acid exposure in the extraesophageal manifestations of reflux. Clin Gastroenterol Hepatol 2012; 10:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42840/abstract/5\">",
"      Cremonini F, Locke GR 3rd, Schleck CD, et al. Relationship between upper gastrointestinal symptoms and changes in body weight in a population-based cohort. Neurogastroenterol Motil 2006; 18:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42840/abstract/6\">",
"      Kjellin A, Ramel S, R&ouml;ssner S, Thor K. Gastroesophageal reflux in obese patients is not reduced by weight reduction. Scand J Gastroenterol 1996; 31:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42840/abstract/7\">",
"      Jacobson BC, Somers SC, Fuchs CS, et al. Body-mass index and symptoms of gastroesophageal reflux in women. N Engl J Med 2006; 354:2340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42840/abstract/8\">",
"      Ness-Jensen E, Lindam A, Lagergren J, Hveem K. Weight loss and reduction in gastroesophageal reflux. A prospective population-based cohort study: the HUNT study. Am J Gastroenterol 2013; 108:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42840/abstract/9\">",
"      Kaltenbach T, Crockett S, Gerson LB. Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach. Arch Intern Med 2006; 166:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42840/abstract/10\">",
"      Eherer AJ, Netolitzky F, H&ouml;genauer C, et al. Positive effect of abdominal breathing exercise on gastroesophageal reflux disease: a randomized, controlled study. Am J Gastroenterol 2012; 107:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42840/abstract/11\">",
"      Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease. Gastroenterology 2008; 135:1392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42840/abstract/12\">",
"      Hunt RH. Importance of pH control in the management of GERD. Arch Intern Med 1999; 159:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42840/abstract/13\">",
"      Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology 2008; 135:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42840/abstract/14\">",
"      Bell NJ, Hunt RH. Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease. Gut 1992; 33:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42840/abstract/15\">",
"      Kahrilas PJ. Gastroesophageal reflux disease. JAMA 1996; 276:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42840/abstract/16\">",
"      Sontag SJ. The medical management of reflux esophagitis. Role of antacids and acid inhibition. Gastroenterol Clin North Am 1990; 19:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42840/abstract/17\">",
"      Kahrilas PJ, Fennerty MB, Joelsson B. High- versus standard-dose ranitidine for control of heartburn in poorly responsive acid reflux disease: a prospective, controlled trial. Am J Gastroenterol 1999; 94:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42840/abstract/18\">",
"      Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112:1798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42840/abstract/19\">",
"      Kahrilas PJ, Howden CW, Hughes N. Response of regurgitation to proton pump inhibitor therapy in clinical trials of gastroesophageal reflux disease. Am J Gastroenterol 2011; 106:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42840/abstract/20\">",
"      Fass R, Fennerty MB, Vakil N. Nonerosive reflux disease--current concepts and dilemmas. Am J Gastroenterol 2001; 96:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42840/abstract/21\">",
"      Richter JE, Campbell DR, Kahrilas PJ, et al. Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease. Arch Intern Med 2000; 160:1803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42840/abstract/22\">",
"      Richter JE, Peura D, Benjamin SB, et al. Efficacy of omeprazole for the treatment of symptomatic acid reflux disease without esophagitis. Arch Intern Med 2000; 160:1810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42840/abstract/23\">",
"      van Pinxteren B, Numans ME, Bonis PA, Lau J. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2000; :CD002095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42840/abstract/24\">",
"      Rohof WO, Bennink RJ, de Ruigh AA, et al. Effect of azithromycin on acid reflux, hiatus hernia and proximal acid pocket in the postprandial period. Gut 2012; 61:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42840/abstract/25\">",
"      Lehmann A. Novel treatments of GERD: focus on the lower esophageal sphincter. Eur Rev Med Pharmacol Sci 2008; 12 Suppl 1:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42840/abstract/26\">",
"      Ciccaglione AF, Marzio L. Effect of acute and chronic administration of the GABA B agonist baclofen on 24 hour pH metry and symptoms in control subjects and in patients with gastro-oesophageal reflux disease. Gut 2003; 52:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42840/abstract/27\">",
"      van Herwaarden MA, Samsom M, Rydholm H, Smout AJ. The effect of baclofen on gastro-oesophageal reflux, lower oesophageal sphincter function and reflux symptoms in patients with reflux disease. Aliment Pharmacol Ther 2002; 16:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42840/abstract/28\">",
"      Zhang Q, Lehmann A, Rigda R, et al. Control of transient lower oesophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in patients with gastro-oesophageal reflux disease. Gut 2002; 50:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42840/abstract/29\">",
"      Cange L, Johnsson E, Rydholm H, et al. Baclofen-mediated gastro-oesophageal acid reflux control in patients with established reflux disease. Aliment Pharmacol Ther 2002; 16:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42840/abstract/30\">",
"      Boeckxstaens GE, Beaumont H, Mertens V, et al. Effects of lesogaberan on reflux and lower esophageal sphincter function in patients with gastroesophageal reflux disease. Gastroenterology 2010; 139:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42840/abstract/31\">",
"      Boeckxstaens GE, Beaumont H, Hatlebakk JG, et al. A novel reflux inhibitor lesogaberan (AZD3355) as add-on treatment in patients with GORD with persistent reflux symptoms despite proton pump inhibitor therapy: a randomised placebo-controlled trial. Gut 2011; 60:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42840/abstract/32\">",
"      Hetzel DJ, Dent J, Reed WD, et al. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988; 95:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42840/abstract/33\">",
"      Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol 2013; 108:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42840/abstract/34\">",
"      Robinson M, Lanza F, Avner D, Haber M. Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996; 124:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42840/abstract/35\">",
"      Dent J, Yeomans ND, Mackinnon M, et al. Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety. Gut 1994; 35:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42840/abstract/36\">",
"      Vigneri S, Termini R, Leandro G, et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 1995; 333:1106.",
"     </a>",
"    </li>",
"    <li>",
"     Ip S, Bonis P, Tatsioni A, et al. Comparative Effectiveness of Management Strategies for Gastroesophageal Reflux Disease. Evidence Report/Technology Assessment No. 1. (Prepared by Tufts-New England Medical Center. Evidence-based Practice Center under Contract No. 290-02-0022.) Rockville, MD: Agency for Healthcare Research and Quality. December 2005 www.effectivehealthcare.ahrq.gov/reports/final.cfm (Accessed on March 28, 2012).",
"    </li>",
"    <li>",
"     Ip S, Chung M, Moorthy D, et al. Comparative effectiveness of management strategies for gastroesophageal reflux disease: Update. (Prepared by Tufts Medical Center Evidence-based Practice Center under Contract No. HHSA 290-2007-10055-I.) Rockville, MD: Agency for Healthcare Research and Quality. September 2011. Available at: file://www.effectivehealthcare.ahrq.gov/ehc/products/165/755/CER29-GERD_20110926.pdf.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42840/abstract/39\">",
"      Bardhan KD, M&uuml;ller-Lissner S, Bigard MA, et al. Symptomatic gastro-oesophageal reflux disease: double blind controlled study of intermittent treatment with omeprazole or ranitidine. The European Study Group. BMJ 1999; 318:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42840/abstract/40\">",
"      Shaheen NJ, Weinberg DS, Denberg TD, et al. Upper endoscopy for gastroesophageal reflux disease: best practice advice from the clinical guidelines committee of the American College of Physicians. Ann Intern Med 2012; 157:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42840/abstract/41\">",
"      ASGE Standards of Practice Committee, Evans JA, Early DS, et al. The role of endoscopy in Barrett's esophagus and other premalignant conditions of the esophagus. Gastrointest Endosc 2012; 76:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42840/abstract/42\">",
"      Katz PO, Castell DO. Gastroesophageal reflux disease during pregnancy. Gastroenterol Clin North Am 1998; 27:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42840/abstract/43\">",
"      Larson JD, Patatanian E, Miner PB Jr, et al. Double-blind, placebo-controlled study of ranitidine for gastroesophageal reflux symptoms during pregnancy. Obstet Gynecol 1997; 90:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42840/abstract/44\">",
"      Gill SK, O'Brien L, Einarson TR, Koren G. The safety of proton pump inhibitors (PPIs) in pregnancy: a meta-analysis. Am J Gastroenterol 2009; 104:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42840/abstract/45\">",
"      Pasternak B, Hviid A. Use of proton-pump inhibitors in early pregnancy and the risk of birth defects. N Engl J Med 2010; 363:2114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42840/abstract/46\">",
"      Lalkin A, Loebstein R, Addis A, et al. The safety of omeprazole during pregnancy: a multicenter prospective controlled study. Am J Obstet Gynecol 1998; 179:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42840/abstract/47\">",
"      Ruig&oacute;mez A, Garc&iacute;a Rodr&iacute;guez LA, Cattaruzzi C, et al. Use of cimetidine, omeprazole, and ranitidine in pregnant women and pregnancy outcomes. Am J Epidemiol 1999; 150:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42840/abstract/48\">",
"      Diav-Citrin O, Arnon J, Shechtman S, et al. The safety of proton pump inhibitors in pregnancy: a multicentre prospective controlled study. Aliment Pharmacol Ther 2005; 21:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42840/abstract/49\">",
"      DeVault KR, Castell DO, American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005; 100:190.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2258 Version 24.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-221.10.40.232-E5FD8A8851-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_53_42840=[""].join("\n");
var outline_f41_53_42840=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      LIFESTYLE MODIFICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ACID SUPPRESSIVE MEDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Nonerosive gastroesophageal reflux disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Differences in proton pump inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ADJUNCTIVE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1959668\">",
"      Prokinetic agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1959675\">",
"      Reflux inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      TREATMENT OF HELICOBACTER PYLORI INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MAINTENANCE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Intermittent therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H59972519\">",
"      Safety",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H257926783\">",
"      INDICATIONS FOR UPPER ENDOSCOPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      MAJOR SOCIETY RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2258\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2258|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?28/14/28897\" title=\"algorithm 1\">",
"      Medical treatment of GERD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2258|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/33/4635\" title=\"table 1\">",
"      Potency of treatment for GERD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/12/29900\" title=\"table 2A\">",
"      AGAI management GERD 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/14/40173\" title=\"table 2B\">",
"      AGAI management GERD 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/18/29997\" title=\"table 2C\">",
"      AGAI management GERD 3",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/18/17706?source=related_link\">",
"      Approach to refractory gastroesophageal reflux disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/41/22168?source=related_link\">",
"      Clinical manifestations and diagnosis of gastroesophageal reflux in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/8/1161?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of Barrett's esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/31/32250?source=related_link\">",
"      Epidemiology, pathobiology, and clinical manifestations of esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/46/9959?source=related_link\">",
"      Helicobacter pylori and gastroesophageal reflux disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/60/9160?source=related_link\">",
"      Maternal gastrointestinal tract adaptation to pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/28/25034?source=related_link\">",
"      Overview and comparison of the proton pump inhibitors for the treatment of acid-related disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/38/13928?source=related_link\">",
"      Pathophysiology of reflux esophagitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/42/24226?source=related_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux disease) during pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/30/38373?source=related_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/2/24610?source=related_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux disease) in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/31/19954?source=related_link\">",
"      Patient information: H. pylori infection (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/58/14242?source=related_link\">",
"      Patient information: Helicobacter pylori infection and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/57/42905?source=related_link\">",
"      Surgical management of gastroesophageal reflux in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_53_42841="Antiretroviral medications in pregnancy: Nucleoside reverse transcriptase inhibitors";
var content_f41_53_42841=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Antiretroviral medications in pregnancy: Nucleoside reverse transcriptase inhibitors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/53/42841/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/53/42841/contributors\">",
"     Elaine J Abrams, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/53/42841/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/53/42841/contributors\">",
"     Lynne M Mofenson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/53/42841/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/53/42841/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/53/42841/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decisions regarding antiretroviral therapy in the pregnant female are complex and need to take into consideration various factors such as possible changes in pharmacokinetics due to physiologic changes, potential toxicities that may be magnified during pregnancy, and potential toxicity to the fetus",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    newborn.",
"   </p>",
"   <p>",
"    This topic will address data regarding the safety of these agents in pregnancy. Information about other classes of drugs is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/24/18825?source=see_link\">",
"     \"Antiretroviral medications in pregnancy: Protease inhibitors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/44/25290?source=see_link\">",
"     \"Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical outcomes in women who are treated with antiretroviral therapy are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/44/25290?source=see_link\">",
"     \"Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefits of ART for a pregnant woman must be weighed against the risk of adverse events to the woman, fetus, and newborn [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42841/abstract/1\">",
"     1",
"    </a>",
"    ]. ART is important to preserve the health status of the HIV-infected mother and to decrease the risk of perinatal transmission. Discussion of ART selection and treatment considerations in the pregnant HIV-infected female is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/4/15433?source=see_link\">",
"     \"Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/44/25290?source=see_link\">",
"     \"Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinicians are advised to report antiretroviral exposures during pregnancy to the Antiretroviral Pregnancy Registry at",
"    <a class=\"external\" href=\"file://www.apregistry.com/\">",
"     www.APRegistry.com",
"    </a>",
"    ; Telephone 1-800-258-4263 (URL:",
"    <a class=\"external\" href=\"file://www.apregistry.com/\">",
"     file://www.APRegistry.com",
"    </a>",
"    ), to assist in monitoring outcomes of infants born to HIV-infected women receiving these drugs. The registry is a collaborative project of pharmaceutical manufacturers with an advisory committee of obstetric and pediatric practitioners and representatives from the Centers for Disease Control and Prevention and the National Institutes of Health.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     AVAILABLE AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Available NRTIs for the treatment of HIV infection include, in alphabetical order:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/63/31734?source=see_link\">",
"       Abacavir",
"      </a>",
"      (ABC); Ziagen",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/38/14952?source=see_link\">",
"       Didanosine",
"      </a>",
"      (ddI); Videx",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"       Emtricitabine",
"      </a>",
"      (FTC); Emtriva",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"       Lamivudine",
"      </a>",
"      (3TC); Epivir",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"       Stavudine",
"      </a>",
"      (d4T); Zerit",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"       Tenofovir",
"      </a>",
"      (TDF); Viread",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"       Zidovudine",
"      </a>",
"      (ZDV); also known as AZT",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Zalcitabine (ddC), also known as Hivid, is no longer available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MITOCHONDRIAL TOXICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mitochondrial toxicity is a major adverse effect of nucleoside analogue treatment and can lead to myopathy, peripheral neuropathy, and hepatic steatosis with lactic acidosis, which can be life-threatening. Mitochondrial toxicity is a consequence of NRTI binding to various DNA-polymerases, including mitochondrial DNA polymerase gamma, which leads to mitochondrial DNA depletion and dysfunction.",
"   </p>",
"   <p>",
"    The pathogenesis and clinical manifestations of mitochondrial toxicity are discussed elsewhere. This topic will address data specific for pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/40/30345?source=see_link\">",
"     \"Mitochondrial toxicity of HIV nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical disorders linked to mitochondrial toxicity include neuropathy, myopathy, cardiomyopathy, pancreatitis, hepatic steatosis, and lactic acidosis. Among these, symptomatic lactic acidosis and hepatic steatosis is the most serious complication of NRTI administration and may have a female preponderance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42841/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. This clinical syndrome usually occurs after chronic administration of NRTIs (eg, greater than six months). The frequency of lactic acidosis in pregnant HIV-infected women is unknown.",
"   </p>",
"   <p>",
"    The hepatic lactic acidosis syndrome has similarities to the rare, but life-threatening \"HELLP syndrome\" (hemolysis, elevated liver enzymes and low platelets) that occurs in association with fatty liver during the third trimester. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/30/17897?source=see_link\">",
"     \"HELLP syndrome\"",
"    </a>",
"    .) Some data suggest that a disorder of mitochondrial fatty acid oxidation in the mother or her fetus during late pregnancy may play a role in the etiology of acute fatty liver of pregnancy and possibly contribute to susceptibility to antiretroviral-associated mitochondrial toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42841/abstract/4-7\">",
"     4-7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Implicated drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The NRTIs have different affinities for mtDNA polymerase gamma, explaining in part the different propensity of the drugs to induce toxicity. In vitro, the order of strength of inhibiting polymerase gamma for the different NRTIs is: ddI &gt; d4T &ge; ZDV &gt;&gt;&gt; TDF = 3TC = FTC = ABC. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/40/30345?source=see_link\">",
"     \"Mitochondrial toxicity of HIV nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Reports of lactic acidosis during pregnancy have been most closely associated with the dideoxynucleosides,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42841/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. Bristol-Myers Squibb reported three maternal deaths due to lactic acidosis among women who were either pregnant or postpartum and whose therapy during pregnancy included didanosine and stavudine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42841/abstract/8\">",
"     8",
"    </a>",
"    ]. Two cases were also associated with fetal deaths.",
"   </p>",
"   <p>",
"    Due to these case reports, the United States Public Health Service (USPHS) has issued guidelines that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    should not be used during pregnancy unless no other treatment options exist [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42841/abstract/1\">",
"     1",
"    </a>",
"    ]. Clinicians need to be vigilant for symptoms of mitochondrial toxicity, which overlap with commonly associated symptoms of pregnancy (eg, nausea, vomiting, abdominal bloating, fatigue). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/40/30345?source=see_link\">",
"     \"Mitochondrial toxicity of HIV nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients should also be counseled regarding potential symptoms and signs of mitochondrial toxicity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/61/986?source=see_link\">",
"     \"Counseling HIV-infected patients regarding potential side effects of antiretroviral therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     In utero exposure to NRTIs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early reports suggested that infants with exposure to NRTIs in utero might be at risk of developing mitochondrial dysfunction:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study of 1754 uninfected infants born to HIV-infected women identified five infants who developed moderate to severe neurologic disease in the first few months of life after in utero exposure to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"       zidovudine",
"      </a>",
"      with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      ; two of these children died [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/53/42841/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a larger cohort of 4392 uninfected children (including children in the prior cohort) from France, the 18-month incidence of symptoms of mitochondrial toxicity was 0.26 percent and 0.07 percent for mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/53/42841/abstract/12\">",
"       12",
"      </a>",
"      ]. Risk of developing mitochondrial dysfunction was higher in those children who had exposure to",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"        zidovudine",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"        lamivudine",
"       </a>",
"      </span>",
"      compared to zidovudine alone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, clinical studies from the United States and the rest of Europe have not duplicated these reports from France [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42841/abstract/13-18\">",
"     13-18",
"    </a>",
"    ]. For example:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective chart review of deaths occurring among more than 16,000 children born to HIV-infected women with or without antiretroviral therapy exposure, no mortality associated with mitochondrial toxicity was noted; however, most of the infants were only exposed to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"       zidovudine",
"      </a>",
"      alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/53/42841/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the European Collaborative Study of more than 2400 uninfected children, no clinical manifestations suggestive of mitochondrial toxicity were seen in the approximately 40 percent of children who had in utero ART exposure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/53/42841/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, the data regarding clinical syndromes of mitochondrial dysfunction in children exposed to ART in utero are conflicting, although hematologic abnormalities consistent with mitochondrial depletion have been reported (eg, anemia and neutropenia) in studies from both the United States and Europe [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42841/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. Mitochondrial dysfunction should be considered as a potential etiology of neurologic abnormalities in children with past ART exposure, although the association is still not well defined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;One report examined whether nucleoside analog use was associated with an elevated risk of malignancy. Of 9,127 HIV-uninfected French children who were followed for a median of 5.4 years, the overall incidence of cancer in these children did not differ significantly from that of the general population (10 cases observed versus 8.9 and 9.6 expected) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42841/abstract/22\">",
"     22",
"    </a>",
"    ]. The relative risk of cancer was higher in children exposed to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    versus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    monotherapy. The authors concluded that results suggesting associations with specific nucleoside reverse transcriptase inhibitor combinations would need further investigation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     ABACAVIR",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/63/31734?source=see_link\">",
"     Abacavir",
"    </a>",
"    (Ziagen, ABC) is classified as the United States Food and Drug Administration (FDA) pregnancy category C (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"mobipreview.htm?16/42/17068\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Carcinogenicity animal studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;In long-term carcinogenicity studies, malignant genital tumors (preputial and clitoral gland tumors) were observed in rodents. Malignant hepatic tumors as well as non-malignant hepatic and thyroid tumors were also observed in female rats. The tumors were seen at doses that were 6 to 32 times higher than human exposure at therapeutic doses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Reproduction/fertility animal studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;No effect on reproduction or fertility in male or female rodents has been seen at doses of about eight times that of human therapeutic exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Teratogenicity/developmental toxicity animal studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/63/31734?source=see_link\">",
"     Abacavir",
"    </a>",
"    is associated with decreased body weight, anasarca, and skeletal malformations in rodents at doses about 35 times that of human therapeutic exposure.",
"   </p>",
"   <p>",
"    The offspring of female rats treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    (starting at embryo implantation and ending at weaning), showed an increased incidence of stillbirth and lower body weight throughout life. No effects on fetal malformations were noted in the rabbit.",
"   </p>",
"   <p>",
"    In the Antiretroviral Pregnancy Registry, sufficient data on first trimester exposures to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    are available to exclude a twofold or more increase in birth defects; the prevalence of birth defects with first trimester abacavir exposures in the Registry is 3.2 percent (95% CI 2.1-4.7), which is comparable with the prevalence of birth defects in the US population based on CDC surveillance (2.7 per 100 live births) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42841/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Placental passage",
"    </span>",
"    &nbsp;&mdash;&nbsp;ABC crosses the placenta in rats; there are no data in humans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Breast milk passage",
"    </span>",
"    &nbsp;&mdash;&nbsp;ABC is excreted into the breast milk of lactating rats; there are no data in humans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Human studies in pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a pharmacokinetic study of 25 HIV-infected pregnant women, pregnancy did not affect",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    exposure during the third trimester of pregnancy or at 6 to 12 weeks postpartum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42841/abstract/24\">",
"     24",
"    </a>",
"    ]. Thus, pregnancy does not appear to necessitate dose adjustments.",
"   </p>",
"   <p>",
"    Serious hypersensitivity reactions have been associated with ABC therapy in non-pregnant adults and have rarely been fatal; symptoms include fever, skin rash, fatigue, and gastrointestinal symptoms such as nausea, vomiting, diarrhea, or abdominal pain. Testing for HLA-B*5701 identifies patients at risk of an",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    hypersensitivity reaction; this assay should be performed and documented as negative before starting abacavir [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42841/abstract/1\">",
"     1",
"    </a>",
"    ]. Furthermore, abacavir should not be restarted following history of a hypersensitivity reaction (even with a negative HLA-B*5701test) because more severe symptoms will recur within hours and may include life-threatening hypotension and death. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/35/21049?source=see_link\">",
"     \"Abacavir hypersensitivity reaction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DIDANOSINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/38/14952?source=see_link\">",
"     Didanosine",
"    </a>",
"    (Videx, ddI) is classified as FDA pregnancy category B (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"mobipreview.htm?16/42/17068\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Carcinogenicity animal studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term animal carcinogenicity screening studies in rodents given",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    have been negative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Reproduction/fertility animal studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has been no effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    on reproduction or fertility in rodents or on preimplantation mouse embryos [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42841/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Teratogenicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;No evidence of teratogenicity or toxicity has been observed.",
"   </p>",
"   <p>",
"    Among cases of first trimester ddI exposure reported to the Antiretroviral Pregnancy Registry, defects have been noted in 4.6 percent in 409 women with first trimester exposure, slightly elevated compared to the prevalence of birth defects in the US population based on CDC surveillance (2.7 per 100 live births) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42841/abstract/23\">",
"     23",
"    </a>",
"    ]. All defects were reviewed in detail by the Registry, and no specific pattern of defects was observed. However, these data do suggest a higher risk of birth defects with exposure to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    in the first trimester; trends in association with didanosine are continuing to be monitored by the Registry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42841/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Placental passage",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a phase",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    safety and pharmacokinetic study in humans, placental transfer of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    was limited (newborn:mother drug ratio, 0.35 &plusmn; 0.11) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42841/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Breast milk passage",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/38/14952?source=see_link\">",
"     Didanosine",
"    </a>",
"    is excreted in the milk of lactating rats; it is not known if didanosine is excreted in human breast milk; there are no data in humans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Human studies in pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A phase I study (PACTG 249) was conducted in 14 HIV-infected pregnant women enrolled at gestational age 26 to 36 weeks and treated through six weeks postpartum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42841/abstract/26\">",
"     26",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/38/14952?source=see_link\">",
"     Didanosine",
"    </a>",
"    was well tolerated during pregnancy by the woman and the fetus. Pharmacokinetic parameters after oral administration were not significantly affected by pregnancy; dose modification is not needed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42841/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cases of lactic acidosis, in some cases fatal, have been described in pregnant women receiving the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    along with other antiretroviral agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42841/abstract/9,10,27\">",
"     9,10,27",
"    </a>",
"    ]; the FDA and Bristol Myers Squibb issued a warning to health care officials that pregnant women may be at increased risk of fatal lactic acidosis when prescribed this combination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42841/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Mitochondrial toxicity'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     EMTRICITABINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"     Emtricitabine",
"    </a>",
"    (Emtriva, FTC) is classified as FDA pregnancy category B (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"mobipreview.htm?16/42/17068\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Carcinogenicity animal studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carcinogenicity screening studies have been negative;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    is not genotoxic in in vitro studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Reproduction/fertility animal studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;No effect on reproduction or fertility in rodents has been demonstrated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Teratogenicity/developmental toxicity animal studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence of teratogenicity to date.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Placental passage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Placental passage has been documented in mice and rabbits.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Breast milk passage",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is unknown if",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    is excreted into human breast milk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Human studies in pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no pharmacokinetic studies of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    in pregnancy.",
"   </p>",
"   <p>",
"    The pharmaceutical company is aware of 53 pregnancies in women exposed to FTC. The majority of pregnancies were electively terminated; however, 19 healthy live births were reported. There were six spontaneous abortions; in each of these cases, the patient was receiving multiple antiretroviral agents, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    . Therefore, the specific role of emtricitabine in these outcomes could not be determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     LAMIVUDINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     Lamivudine",
"    </a>",
"    (Epivir, 3TC) is classified as FDA pregnancy category C (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"mobipreview.htm?16/42/17068\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Carcinogenicity animal studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term animal carcinogenicity screening studies in rodents administered 3TC have been negative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Reproduction/fertility animal studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;There appears to be no effect on reproduction or fertility in rodents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Teratogenicity/developmental toxicity animal studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence of teratogenicity. Early embryo-lethality was seen in rabbits, but not rats, at doses similar to human therapeutic exposure.",
"   </p>",
"   <p>",
"    In the Antiretroviral Pregnancy Registry, sufficient data on first trimester exposures to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    are available to exclude a 1.5-fold or more increase in birth defects; the prevalence of birth defects with first trimester lamivudine exposures in the Registry is 3.1 percent (95% CI 2.6-3.7), which is comparable with the prevalence of birth defects in the US population based on CDC surveillance (2.7 per 100 live births) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42841/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Placental passage",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     Lamivudine",
"    </a>",
"    crosses the placenta in humans, achieving comparable cord blood and maternal concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42841/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Breast milk passage",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     Lamivudine",
"    </a>",
"    is excreted into human breast milk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42841/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. One study in Botswana demonstrated that the median breast milk concentration of lamivudine threefold higher than in maternal serum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42841/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Human studies in pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small phase I study in South Africa evaluated the safety and pharmacokinetics of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    alone or in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    in 20 HIV-infected pregnant women when started at 38 weeks gestation and continued through labor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42841/abstract/28\">",
"     28",
"    </a>",
"    ]. Zidovudine and lamivudine were well tolerated. Pharmacokinetics for lamivudine were similar to nonpregnant females, and no drug interactions with zidovudine were observed.",
"   </p>",
"   <p>",
"    In a larger pharmacokinetic study of 114 pregnant and 47 nonpregnant women on long-term antiretroviral therapy that included",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    , rate of clearance of lamivudine was 22 percent higher during pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42841/abstract/31\">",
"     31",
"    </a>",
"    ]. Accordingly, plasma lamivudine levels were lower in pregnant women but comparable to levels historically observed in other nonpregnant adults. No changes in dosing are required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     STAVUDINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"     Stavudine",
"    </a>",
"    (Zerit, d4T) is classified as FDA pregnancy category C (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"mobipreview.htm?16/42/17068\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Carcinogenicity animal studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;In two-year carcinogenicity studies in mice and rats, d4T was noncarcinogenic in doses producing exposures 39 to 168 times human exposure at the recommended therapeutic dose. Higher levels of exposure led to liver and bladder tumors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Reproduction/fertility animal studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;No effect on reproduction or fertility in rodents has been seen. A dose-related cytotoxic effect on preimplantation mouse embryos with inhibition of blastocyst formation and postblastocyst development has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42841/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Teratogenicity/developmental toxicity animal studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;No evidence of teratogenicity has been observed in pregnant rats and rabbits. Developmental toxicity, consisting of a small increase in neonatal mortality and minor skeletal ossification delay, occurred at the highest dose in rats.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Placental passage",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"     Stavudine",
"    </a>",
"    crosses the placenta in rats and primates; fetal to maternal plasma concentrations of 0.8 have been documented in pigtailed macaques [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42841/abstract/30\">",
"     30",
"    </a>",
"    ]. In a phase I study in humans, the cord:maternal stavudine ratio was 1.3 &plusmn; 0.3, indicating good to excellent passage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Breast milk passage",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"     Stavudine",
"    </a>",
"    is excreted into the breast milk of lactating rats; there are no data in humans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Human studies in pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A phase",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    safety and pharmacokinetic study of combination",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    was conducted in 14 mother-infant pairs who were intolerant of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    (PACTG 332) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42841/abstract/32\">",
"     32",
"    </a>",
"    ]. Both drugs were well tolerated, with pharmacokinetics similar to those in non-pregnant adults; no changes in dose are indicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42841/abstract/32\">",
"     32",
"    </a>",
"    ]. Like zidovudine and lamivudine, stavudine efficiently crossed the placenta.",
"   </p>",
"   <p>",
"    As noted above in the discussion of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    , the FDA and Bristol Myers Squibb issued a warning to health care professionals that pregnant women may be at increased risk of fatal lactic acidosis when prescribed the combination of didanosine and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42841/abstract/32\">",
"     32",
"    </a>",
"    ]. The combination of these two drugs should be prescribed for pregnant women only when the potential benefit clearly outweighs the potential risk (eg, no other available therapeutic options).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h1\">",
"     TENOFOVIR",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     Tenofovir",
"    </a>",
"    DF (Viread) is classified as FDA pregnancy category B (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"mobipreview.htm?16/42/17068\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h2\">",
"     Carcinogenicity animal studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term carcinogenicity studies have demonstrated an increased incidence of liver adenomas in mice at exposures 16 times that observed in humans at therapeutic doses. At lower doses, no carcinogenicity was found in rats.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h2\">",
"     Reproduction/fertility animal studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;No adverse effects on fertility or reproduction were observed in rats or rabbits. However, there was an alteration of the estrous cycle in female rats administered 600",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h2\">",
"     Teratogenicity/developmental toxicity animal studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     Tenofovir",
"    </a>",
"    has not demonstrated teratogenicity in rodents, monkeys, or rhesus macaques [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42841/abstract/33\">",
"     33",
"    </a>",
"    ]. When tenofovir was administered to pregnant rats in maternally toxic doses, reduced survival was seen in the offspring; no adverse effects were seen when tenofovir was administered at lower doses.",
"   </p>",
"   <p>",
"    Exposure of fetal monkeys to high-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    during gestation did not result in gross structural abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42841/abstract/34\">",
"     34",
"    </a>",
"    ]. However, significantly lower fetal circulating insulin-like growth factor (IGF)-1 (a primary regulator of linear growth) and higher IGF binding protein (IGFBP)-3 levels were associated with lower overall body weights compared to untreated controls. Continued administration of tenofovir postnatally resulted in significant growth restriction and severe bone toxicity in two of eight infant monkeys.",
"   </p>",
"   <p>",
"    Chronic administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    to immature animals of multiple species has resulted in reversible bone abnormalities; these effects were dose-, exposure-, age- and species-specific. Abnormalities ranged from a minimal decrease in bone mineral density and content to severe osteomalacia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42841/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nephrotoxicity has been observed in newborn and juvenile monkeys given",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    in doses resulting in exposures 12 to 50 times higher than the human dose.",
"   </p>",
"   <p>",
"    In the Antiretroviral Pregnancy Registry, sufficient data on first trimester exposures to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    are available to exclude a twofold or more increase in birth defects; the prevalence of birth defects with first trimester tenofovir exposures in the Registry is 2.2 percent (95% CI 1.5-3.2), which is comparable with the prevalence of birth defects in the US population based on CDC surveillance (2.7 per 100 live births) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42841/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h2\">",
"     Placental passage",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     Tenofovir",
"    </a>",
"    crosses the placenta in monkeys, with a",
"    <span class=\"nowrap\">",
"     fetal/maternal",
"    </span>",
"    concentration of 17 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42841/abstract/36\">",
"     36",
"    </a>",
"    ]. Significant placental passage occurs in humans (cord:maternal blood ratio of approximately 1.0) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42841/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h2\">",
"     Breast milk passage",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     Tenofovir",
"    </a>",
"    is secreted into the breast milk of lactating rats; there are no data in humans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50\">",
"    <span class=\"h2\">",
"     Human studies in pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from the Antiretroviral Pregnancy Registry on 1092 pregnancies with first-trimester exposure to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    have shown no increase in overall birth defects compared with the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42841/abstract/23\">",
"     23",
"    </a>",
"    ]. Studies evaluating the longer term effects of intrauterine tenofovir exposure have demonstrated conflicting results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In 449 infants born to HIV-infected mothers who received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      compared with infants whose mothers received non-tenofovir containing ART regimens during pregnancy, there were no differences in the following parameters: small for gestational age, low birth weight, and z-score for length and head circumference at birth [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/53/42841/abstract/37\">",
"       37",
"      </a>",
"      ]. However, at age one year, infants exposed to tenofovir versus unexposed had significantly lower adjusted z-scores for mean length (-0.17 versus -0.03) and head circumference (0.17 versus 0.42). &nbsp;",
"     </li>",
"     <li>",
"      A smaller study of 33",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      -exposed infants similarly found no difference in anthropomorphic parameters at birth or in bone parameters in tenofovir versus non-tenofovir-exposed infants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/53/42841/abstract/38\">",
"       38",
"      </a>",
"      ]. In contrast to the above study, it did not find differences in growth parameters at a median age of 11 months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further studies are ongoing to evaluate both bone mineral density and growth in",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    -exposed infants. However, in light of animal studies (described above) that show decreased fetal growth and reduction in fetal bone porosity and studies in infected children on chronic tenofovir-based therapy that show bone demineralization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42841/abstract/39\">",
"     39",
"    </a>",
"    ], tenofovir is considered a second-line NRTI during pregnancy for antiretroviral-na&iuml;ve women. However, for pregnant women with chronic hepatitis B infection, tenofovir in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    would be the preferred NRTI backbone of a combination antiretroviral regimen due to the dual anti-hepatitis B activity of the combination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42841/abstract/40\">",
"     40",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    A population pharmacokinetic study of 46 pregnant and 156 nonpregnant women on long-term antiretroviral therapy including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    showed a 39 percent greater clearance of the tenofovir during pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42841/abstract/41\">",
"     41",
"    </a>",
"    ]. This resulted in lower trough concentrations in the pregnant women (0.04 versus 0.06",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    in nonpregnant women). However, no data on virologic response in this study was reported. Other studies have found lower area under the curve concentrations during the third trimester than postpartum, but trough levels were similar [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42841/abstract/42\">",
"     42",
"    </a>",
"    ]. At the present time, standard tenofovir dosing during pregnancy is recommended, with virologic monitoring to ensure suppression is achieved. &nbsp;",
"   </p>",
"   <p>",
"    Additional pharmacokinetic studies of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    in pregnancy are underway. Tenofovir given during labor was well tolerated in two studies of pregnant women in resource-limited settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42841/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51\">",
"    <span class=\"h1\">",
"     ZIDOVUDINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"     Zidovudine",
"    </a>",
"    (Retrovir) is classified as FDA pregnancy category C (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"mobipreview.htm?16/42/17068\">",
"     table 1",
"    </a>",
"    ). Zidovudine is considered a \"preferred\" NRTI for use in pregnancy due to extensive data regarding safety and efficacy. It is recommended as a component of ART unless there is significant associated toxicity or potential for drug interactions (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/44/25290?source=see_link\">",
"     \"Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H52\">",
"    <span class=\"h2\">",
"     Carcinogenicity animal studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"     Zidovudine",
"    </a>",
"    has carcinogenic potential through evidence gathered from in vitro and animal screening tests. Prolonged, continuous, high-dose zidovudine administration to adult rodents is associated with the development of vaginal squamous tumors in 13 percent of female rodents (at estimated drug concentrations 3 and 24 times that of human therapeutic exposure in mice and rats, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42841/abstract/45\">",
"     45",
"    </a>",
"    ]. A subsequent study demonstrated an increase in lung, liver, and female reproductive tumors in the offspring of mice who were exposed to very high daily doses of drug (25 to 50 times that of the human therapeutic dose) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42841/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relevance of these data to humans is unknown. No tumors have been observed in 727 children with in utero ZDV exposure followed for over 1100 person-years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42841/abstract/47\">",
"     47",
"    </a>",
"    ]. While these data are reassuring, follow-up is still limited and needs to be continued into adulthood before it can be concluded that there is no carcinogenic risk.",
"   </p>",
"   <p>",
"    In January 1997, the National Institutes of Health convened an expert panel to review these animal data [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42841/abstract/48\">",
"     48",
"    </a>",
"    ]. The panel concluded that the known benefit of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    in reducing HIV perinatal transmission far outweighed the theoretical risks of transplacental carcinogenicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42841/abstract/49\">",
"     49",
"    </a>",
"    ]. The panel also concluded that infants with in utero exposure to ZDV (or any other antiretroviral) should have long-term follow-up for potential adverse effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53\">",
"    <span class=\"h2\">",
"     Reproduction/fertility animal studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;No effect on reproduction or fertility in rodents has been seen. A dose-related cytotoxic effect on preimplantation mouse embryos can occur, with inhibition of blastocyst and postblastocyst development at concentrations similar to that achieved with human therapeutic doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42841/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H54\">",
"    <span class=\"h2\">",
"     Teratogenicity/developmental toxicity animal studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;No evidence of teratogenicity or toxicity has been observed in animal models.",
"   </p>",
"   <p>",
"    In humans, data from PACTG 076 and the Antiretroviral Pregnancy Registry do not demonstrate an increased incidence of congenital abnormalities in infants born to women with antepartum ZDV exposure over the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42841/abstract/13,35,49,51\">",
"     13,35,49,51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55\">",
"    <span class=\"h2\">",
"     Placental passage",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"     Zidovudine",
"    </a>",
"    rapidly crosses the human placenta, achieving cord-to-maternal blood ratios of about 0.80.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56\">",
"    <span class=\"h2\">",
"     Breast milk passage",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"     Zidovudine",
"    </a>",
"    is excreted into human breast milk. In a study of breastfeeding women receiving combination antiretroviral therapy in Botswana, the median breast milk concentration of zidovudine was threefold higher than that in maternal serum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42841/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H57\">",
"    <span class=\"h2\">",
"     Human studies in pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the landmark studies in HIV research included Pediatric AIDS Clinical Trial Group (PACTG) 076, which demonstrated that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    administration during pregnancy and labor reduced the risk of HIV perinatal transmission by nearly 70 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42841/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"     Zidovudine",
"    </a>",
"    is well tolerated in pregnancy at recommended adult doses and in the full-term neonate at 2 mg per kg body weight orally every six hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42841/abstract/49,52\">",
"     49,52",
"    </a>",
"    ]. The pharmacokinetics of zidovudine do not appear to be changed during pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42841/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Long-term data on the safety of in utero drug exposure in humans are not available for any antiretroviral drug; however, short-term data on the safety of ZDV are reassuring. Infants with in utero ZDV exposure followed for nearly six years have shown no significant differences from those who received placebo in immunologic, neurologic and growth parameters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42841/abstract/13,53\">",
"     13,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, one prospective study of infants born to HIV-infected mothers (exposed or not exposed to ZDV) showed no myocardial abnormalities or dysfunction attributable to ZDV when these infants were followed by serial echocardiography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/53/42841/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here is the patient education article that is relevant to this topic. We encourage you to print or e-mail this topic to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/29/7635?source=see_link\">",
"       \"Patient information: HIV and pregnancy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Decisions regarding antiretroviral therapy in the pregnant female are complex and need to take into consideration changes in pharmacokinetics and potential toxicities to the mother and fetus. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      ART is important to preserve the health status of the HIV-infected mother and to decrease the risk of perinatal transmission. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mitochondrial toxicity can occur with chronic administration of nucleoside analogs and can result in lactic acidosis and hepatic steatosis, which can be potentially fatal. The dideoxynucleosides (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/38/14952?source=see_link\">",
"       didanosine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"       stavudine",
"      </a>",
"      ) are most closely associated with this syndrome, particularly when used together. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Mitochondrial toxicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      No effect on reproductive function or fertility has been described with the NRTIs.",
"     </li>",
"     <li>",
"      Most NRTIs do not appear to be associated with an increase in birth defects compared with the general population. Data from the Antiretroviral Pregnancy Registry suggest that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/38/14952?source=see_link\">",
"       didanosine",
"      </a>",
"      use in the first trimester may be associated with a slightly increased incidence of birth defects, although no pattern of congenital defects has been observed.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"       Lamivudine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"       stavudine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"       zidovudine",
"      </a>",
"      all cross the placenta achieving significant concentrations in cord blood.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/7/38007?source=see_link\">",
"       Lamivudine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"       stavudine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/28/24008?source=see_link\">",
"       zidovudine",
"      </a>",
"      all achieve significant concentrations in breast milk.",
"     </li>",
"     <li>",
"      None of the NRTIs require dose adjustment in pregnancy.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Public Health Service Task Force Recommendations for use of Antiretroviral Drugs in Pregnant HIV-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. September 14, 2011. www.AIDSInfo.nih.gov (Accessed on March 16, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42841/abstract/2\">",
"      Currier JS. Sex differences in antiretroviral therapy toxicity: lactic acidosis, stavudine, and women. Clin Infect Dis 2007; 45:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42841/abstract/3\">",
"      Bolhaar MG, Karstaedt AS. A high incidence of lactic acidosis and symptomatic hyperlactatemia in women receiving highly active antiretroviral therapy in Soweto, South Africa. Clin Infect Dis 2007; 45:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42841/abstract/4\">",
"      Ibdah JA, Bennett MJ, Rinaldo P, et al. A fetal fatty-acid oxidation disorder as a cause of liver disease in pregnant women. N Engl J Med 1999; 340:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42841/abstract/5\">",
"      Strauss AW, Bennett MJ, Rinaldo P, et al. Inherited long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency and a fetal-maternal interaction cause maternal liver disease and other pregnancy complications. Semin Perinatol 1999; 23:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42841/abstract/6\">",
"      Sims HF, Brackett JC, Powell CK, et al. The molecular basis of pediatric long chain 3-hydroxyacyl-CoA dehydrogenase deficiency associated with maternal acute fatty liver of pregnancy. Proc Natl Acad Sci U S A 1995; 92:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42841/abstract/7\">",
"      Ibdah JA, Yang Z, Bennett MJ. Liver disease in pregnancy and fetal fatty acid oxidation defects. Mol Genet Metab 2000; 71:182.",
"     </a>",
"    </li>",
"    <li>",
"     Bristol-Myers Squibb Company. Heatlhcare Provider Important Drug Warning Letter. January 5, 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42841/abstract/9\">",
"      Sarner L, Fakoya A. Acute onset lactic acidosis and pancreatitis in the third trimester of pregnancy in HIV-1 positive women taking antiretroviral medication. Sex Transm Infect 2002; 78:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42841/abstract/10\">",
"      Mandelbrot L, Kermarrec N, Marcollet A, et al. Case report: nucleoside analogue-induced lactic acidosis in the third trimester of pregnancy. AIDS 2003; 17:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42841/abstract/11\">",
"      Blanche S, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 1999; 354:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42841/abstract/12\">",
"      Barret B, Tardieu M, Rustin P, et al. Persistent mitochondrial dysfunction in HIV-1-exposed but uninfected infants: clinical screening in a large prospective cohort. AIDS 2003; 17:1769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42841/abstract/13\">",
"      Sperling RS, Shapiro DE, McSherry GD, et al. Safety of the maternal-infant zidovudine regimen utilized in the Pediatric AIDS Clinical Trial Group 076 Study. AIDS 1998; 12:1805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42841/abstract/14\">",
"      Nucleoside exposure in the children of HIV-infected women receiving antiretroviral drugs: absence of clear evidence for mitochondrial disease in children who died before 5 years of age in five United States cohorts. J Acquir Immune Defic Syndr 2000; 25:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42841/abstract/15\">",
"      Lipshultz SE, Easley KA, Orav EJ, et al. Absence of cardiac toxicity of zidovudine in infants. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection Study Group. N Engl J Med 2000; 343:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42841/abstract/16\">",
"      European Collaborative Study. Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women. J Acquir Immune Defic Syndr 2003; 32:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42841/abstract/17\">",
"      Alimenti A, Forbes JC, Oberlander TF, et al. A prospective controlled study of neurodevelopment in HIV-uninfected children exposed to combination antiretroviral drugs in pregnancy. Pediatrics 2006; 118:e1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42841/abstract/18\">",
"      Brogly SB, Ylitalo N, Mofenson LM, et al. In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected children. AIDS 2007; 21:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42841/abstract/19\">",
"      Pacheco SE, McIntosh K, Lu M, et al. Effect of perinatal antiretroviral drug exposure on hematologic values in HIV-uninfected children: An analysis of the women and infants transmission study. J Infect Dis 2006; 194:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42841/abstract/20\">",
"      European Collaborative Study. Levels and patterns of neutrophil cell counts over the first 8 years of life in children of HIV-1-infected mothers. AIDS 2004; 18:2009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42841/abstract/21\">",
"      Mandelbrot L, Landreau-Mascaro A, Rekacewicz C, et al. Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1. JAMA 2001; 285:2083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42841/abstract/22\">",
"      Benhammou V, Warszawski J, Bellec S, et al. Incidence of cancer in children perinatally exposed to nucleoside reverse transcriptase inhibitors. AIDS 2008; 22:2165.",
"     </a>",
"    </li>",
"    <li>",
"     Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry International Interim Report for 1 January 1989 through 31 July 2011. Wilmington, NC: Registry Coordinating Center; 2011. www.apregistry.com/who.htm (Accessed on March 16, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42841/abstract/24\">",
"      Best BM, Mirochnick M, Capparelli EV, et al. Impact of pregnancy on abacavir pharmacokinetics. AIDS 2006; 20:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42841/abstract/25\">",
"      Toltzis P, Mourton T, Magnuson T. Comparative embryonic cytotoxicity of antiretroviral nucleosides. J Infect Dis 1994; 169:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42841/abstract/26\">",
"      Wang Y, Livingston E, Patil S, et al. Pharmacokinetics of didanosine in antepartum and postpartum human immunodeficiency virus--infected pregnant women and their neonates: an AIDS clinical trials group study. J Infect Dis 1999; 180:1536.",
"     </a>",
"    </li>",
"    <li>",
"     Zerit, Videx to carry black-box warnings against combined use in pregnancy. In: \"The Pink Sheet\" Vol.63, No. 2. F-D-C Reports, Inc. Chevy Chase, MD 2001. p.27.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42841/abstract/28\">",
"      Moodley J, Moodley D, Pillay K, et al. Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring. J Infect Dis 1998; 178:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42841/abstract/29\">",
"      Shapiro RL, Holland DT, Capparelli E, et al. Antiretroviral concentrations in breast-feeding infants of women in Botswana receiving antiretroviral treatment. J Infect Dis 2005; 192:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42841/abstract/30\">",
"      Mirochnick M, Thomas T, Capparelli E, et al. Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy. Antimicrob Agents Chemother 2009; 53:1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42841/abstract/31\">",
"      Benaboud S, Tr&eacute;luyer JM, Urien S, et al. Pregnancy-related effects on lamivudine pharmacokinetics in a population study with 228 women. Antimicrob Agents Chemother 2012; 56:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42841/abstract/32\">",
"      Odinecs A, Nosbisch C, Keller RD, et al. In vivo maternal-fetal pharmacokinetics of stavudine (2',3'-didehydro-3'-deoxythymidine) in pigtailed macaques (Macaca nemestrina). Antimicrob Agents Chemother 1996; 40:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42841/abstract/33\">",
"      Van Rompay KK, Durand-Gasselin L, Brignolo LL, et al. Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: summary of pharmacokinetics and biological and virological effects. Antimicrob Agents Chemother 2008; 52:3144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42841/abstract/34\">",
"      Tarantal AF, Castillo A, Ekert JE, et al. Fetal and maternal outcome after administration of tenofovir to gravid rhesus monkeys (Macaca mulatta). J Acquir Immune Defic Syndr 2002; 29:207.",
"     </a>",
"    </li>",
"    <li>",
"     Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral pregnancy registry international interim report for 1 Jan 1989 - 31 January 2008. Wilmington, NC: Registry Coordinating Center; 2008. file://www.APRegistry.com (Accessed on February 11, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42841/abstract/36\">",
"      Tarantal AF, Marthas ML, Shaw JP, et al. Administration of 9-[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) to gravid and infant rhesus macaques (Macaca mulatta): safety and efficacy studies. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42841/abstract/37\">",
"      Siberry GK, Williams PL, Mendez H, et al. Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants. AIDS 2012; 26:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42841/abstract/38\">",
"      Vigan&ograve; A, Mora S, Giacomet V, et al. In utero exposure to tenofovir disoproxil fumarate does not impair growth and bone health in HIV-uninfected children born to HIV-infected mothers. Antivir Ther 2011; 16:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42841/abstract/39\">",
"      Gafni RI, Hazra R, Reynolds JC, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. Pediatrics 2006; 118:e711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42841/abstract/40\">",
"      Piroth L, Mahy S, Pol S, et al. Current management and recommendations on hepatitis B therapy in HIV-coinfected patients. Hepatol Int 2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42841/abstract/41\">",
"      Benaboud S, Hirt D, Launay O, et al. Pregnancy-related effects on tenofovir pharmacokinetics: a population study with 186 women. Antimicrob Agents Chemother 2012; 56:857.",
"     </a>",
"    </li>",
"    <li>",
"     Burchett SK, Best B, et al. Tenofovir Pharmacokinetics During Pregnancy, at Delivery and Postpartum. The 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42841/abstract/43\">",
"      TEmAA ANRS 12109 Study group, Arriv&eacute; E, Chaix ML, et al. Tolerance and viral resistance after single-dose nevirapine with tenofovir and emtricitabine to prevent vertical transmission of HIV-1. AIDS 2009; 23:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42841/abstract/44\">",
"      Chi BH, Sinkala M, Mbewe F, et al. Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial. Lancet 2007; 370:1698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42841/abstract/45\">",
"      Ayers KM, Clive D, Tucker WE Jr, et al. Nonclinical toxicology studies with zidovudine: genetic toxicity tests and carcinogenicity bioassays in mice and rats. Fundam Appl Toxicol 1996; 32:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42841/abstract/46\">",
"      Olivero OA, Anderson LM, Diwan BA, et al. Transplacental effects of 3'-azido-2',3'-dideoxythymidine (AZT): tumorigenicity in mice and genotoxicity in mice and monkeys. J Natl Cancer Inst 1997; 89:1602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42841/abstract/47\">",
"      Hanson IC, Antonelli TA, Sperling RS, et al. Lack of tumors in infants with perinatal HIV-1 exposure and fetal/neonatal exposure to zidovudine. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42841/abstract/48\">",
"      Reggy AA, Rogers MF, Simonds RJ. Using 3'-azido-2',3'-dideoxythymidine (AZT) to prevent perinatal human immunodeficiency virus transmission and risk of transplacental carcinogenesis. J Natl Cancer Inst 1997; 89:1566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42841/abstract/49\">",
"      Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994; 331:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42841/abstract/50\">",
"      Toltzis P, Marx CM, Kleinman N, et al. Zidovudine-associated embryonic toxicity in mice. J Infect Dis 1991; 163:1212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42841/abstract/51\">",
"      White A, Eldridge R, Andrews E. Birth outcomes following zidovudine exposure in pregnant women: the Antiretroviral Pregnancy Registry. Acta Paediatr Suppl 1997; 421:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42841/abstract/52\">",
"      O'Sullivan MJ, Boyer PJ, Scott GB, et al. The pharmacokinetics and safety of zidovudine in the third trimester of pregnancy for women infected with human immunodeficiency virus and their infants: phase I acquired immunodeficiency syndrome clinical trials group study (protocol 082). Zidovudine Collaborative Working Group. Am J Obstet Gynecol 1993; 168:1510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/53/42841/abstract/53\">",
"      Culnane M, Fowler M, Lee SS, et al. Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. Pediatric AIDS Clinical Trials Group Protocol 219/076 Teams. JAMA 1999; 281:151.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3778 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-89.32.226.102-D86B8ADF8C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_53_42841=[""].join("\n");
var outline_f41_53_42841=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H59\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      AVAILABLE AGENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MITOCHONDRIAL TOXICITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Implicated drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      In utero exposure to NRTIs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      ABACAVIR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Carcinogenicity animal studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Reproduction/fertility animal studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Teratogenicity/developmental toxicity animal studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Placental passage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Breast milk passage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Human studies in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DIDANOSINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Carcinogenicity animal studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Reproduction/fertility animal studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Teratogenicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Placental passage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Breast milk passage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Human studies in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      EMTRICITABINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Carcinogenicity animal studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Reproduction/fertility animal studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Teratogenicity/developmental toxicity animal studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Placental passage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Breast milk passage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Human studies in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      LAMIVUDINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Carcinogenicity animal studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Reproduction/fertility animal studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Teratogenicity/developmental toxicity animal studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Placental passage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Breast milk passage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Human studies in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      STAVUDINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Carcinogenicity animal studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Reproduction/fertility animal studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Teratogenicity/developmental toxicity animal studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Placental passage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Breast milk passage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Human studies in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      TENOFOVIR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      Carcinogenicity animal studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      Reproduction/fertility animal studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      Teratogenicity/developmental toxicity animal studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      Placental passage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      Breast milk passage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H50\">",
"      Human studies in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H51\">",
"      ZIDOVUDINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H52\">",
"      Carcinogenicity animal studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H53\">",
"      Reproduction/fertility animal studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H54\">",
"      Teratogenicity/developmental toxicity animal studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H55\">",
"      Placental passage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H56\">",
"      Breast milk passage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H57\">",
"      Human studies in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H59\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3778\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3778|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\" title=\"table 1\">",
"      Drug ratings in pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/35/21049?source=related_link\">",
"      Abacavir hypersensitivity reaction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/24/18825?source=related_link\">",
"      Antiretroviral medications in pregnancy: Protease inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/61/986?source=related_link\">",
"      Counseling HIV-infected patients regarding potential side effects of antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/30/17897?source=related_link\">",
"      HELLP syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/40/30345?source=related_link\">",
"      Mitochondrial toxicity of HIV nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?7/29/7635?source=related_link\">",
"      Patient information: HIV and pregnancy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/4/15433?source=related_link\">",
"      Prenatal evaluation and intrapartum management of the HIV-infected patient in resource-rich settings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/44/25290?source=related_link\">",
"      Use of antiretroviral medications in pregnant HIV-infected patients and their infants in resource-rich settings",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_53_42842="Acute lateral MI tutorial";
var content_f41_53_42842=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F82413&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F82413&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1253px;\">",
"  <div class=\"figure\" style=\"width: 539px\">",
"   <div class=\"ttl\">",
"    Acute lateral transmural myocardial infarction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 519px; height: 230px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    ST elevation in leads I and aVL is characteristic of an acute lateral wall infarct. Reciprocal ST depression is evident in this case in the inferior leads (II, III, and aVF) and in V1.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 594px\">",
"   <div class=\"ttl\">",
"    Normal ECG",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 594px; height: 337px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75&deg;.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary Goldberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_53_42842=[""].join("\n");
var outline_f41_53_42842=null;
var title_f41_53_42843="Evaluation of incomplete precocious puberty";
var content_f41_53_42843=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F72054&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F72054&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Evaluation of incomplete precocious puberty",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Etiology",
"       </td>",
"       <td class=\"subtitle1\">",
"        Gonadotropin levels",
"       </td>",
"       <td class=\"subtitle1\">",
"        LH response after GnRH stimulation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Sex steroid hormone levels",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical features",
"       </td>",
"       <td class=\"subtitle1\">",
"        Additional evaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Premature adrenarche",
"       </td>",
"       <td>",
"        Prepubertal LH levels",
"       </td>",
"       <td>",
"        No LH response",
"       </td>",
"       <td>",
"        <p>",
"         DHEAS values elevated for age (at Tanner 2 levels, ie, &gt;50 micrograms/dL)",
"        </p>",
"        <p>",
"         17-OHP and testosterone normal",
"        </p>",
"        <p>",
"         Early pubertal response to ACTH",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         No other signs of pubertal development; normal growth rate",
"        </p>",
"        <p>",
"         Gonads prepubertal",
"        </p>",
"        <p>",
"         Onset usually after six years of age",
"        </p>",
"        <p>",
"         Associated more frequently with brain injury, obesity, or children born SGA",
"        </p>",
"       </td>",
"       <td>",
"        Monitor for possible early progression to full puberty",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Premature thelarche",
"       </td>",
"       <td>",
"        Prepubertal LH levels",
"       </td>",
"       <td>",
"        No LH response, normal FSH response",
"       </td>",
"       <td>",
"        Prepubertal",
"       </td>",
"       <td>",
"        No other signs of pubertal development; normal growth rate",
"       </td>",
"       <td>",
"        Monitor for possible early progression to full puberty",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     LH: luteinizing hormone; GnRH: gonadotropin-releasing hormone; DHEAS: dehydroepiandrosterone sulfate; 17-OHP: 17-hydroxyprogesterone; ACTH: adrenocorticotropic hormone; SGA: small for gestational age; FSH: follicle-stimulating hormone.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_53_42843=[""].join("\n");
var outline_f41_53_42843=null;
var title_f41_53_42844="Prevalence of celiac disease in special populations";
var content_f41_53_42844=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F50751&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F50751&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Prevalence of celiac disease in special populations",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent of group affected",
"       </td>",
"       <td class=\"subtitle1\">",
"        Fold increase in risk as compared to general population",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        General population (US and Europe)",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"       <td>",
"        0.7 to 1.0",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        Relatives of patient with celiac disease",
"        <sup>",
"         [1,2]",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        first-degree relatives",
"       </td>",
"       <td class=\"sublist_other\">",
"        4 to 5",
"       </td>",
"       <td class=\"sublist_other\">",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        second degree relatives",
"       </td>",
"       <td class=\"sublist_other\">",
"        3",
"       </td>",
"       <td class=\"sublist_other\">",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Down syndrome",
"        <sup>",
"         [2,3]",
"        </sup>",
"       </td>",
"       <td>",
"        5 to 16",
"       </td>",
"       <td>",
"        7 to 21",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Type 1 diabetes",
"        <sup>",
"         [2,4]",
"        </sup>",
"       </td>",
"       <td>",
"        5 to 10",
"       </td>",
"       <td>",
"        7 to 13",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IgA deficiency",
"        <sup>",
"         [2,5]",
"        </sup>",
"       </td>",
"       <td>",
"        2 to 8",
"       </td>",
"       <td>",
"        3 to 11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Williams syndrome",
"        <sup>",
"         [6]",
"        </sup>",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Turner syndrome",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"       <td>",
"        4 to 8",
"       </td>",
"       <td>",
"        5 to 11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Autoimmune thyroid disease",
"        <sup>",
"         [7]",
"        </sup>",
"       </td>",
"       <td>",
"        4.5",
"       </td>",
"       <td>",
"        6 (less in children)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      1. Fasano A, Berti I, Gerarduzzi T, et al. Prevalence of celiac disease in at-risk and not-at-risk groups in the United States: A large multicenter study. Arch Intern Med 2003; 163:286.",
"      <br>",
"       2. Hill ID, Dirks MH, Liptak GS, et al. Guideline for the diagnosis and treatment of celiac disease in children: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2005; 40:1.",
"       <br>",
"        3. Carlsson A, Axelsson I, Boruls S, et al. Prevalence of IgA-antigliadin antibodies and IgA-antiendomysium antibodies related to celiac disease in children with Down syndrome. Pediatrics 1998; 101:272.",
"        <br>",
"         4. Crone J, Rami B, Huber WD, et al. Prevalence of celiac disease and follow-up of EMA in children and adolescents with type 1 diabetes mellitus. J Pediatr Gastroenterol Nutr 2003; 37:67.",
"         <br>",
"          5. Meini A, Pillan NM, Villanacci V, et al. Prevalence and diagnosis of celiac disease in IgA-deficient children. Ann Allergy Asthma Immunol 1996; 77:333.",
"          <br>",
"           6. Giannotti A, Tiberio G, Castro M, et al. Coeliac disease in Williams syndrome. J Med Genet 2001; 38:767.",
"           <br>",
"            7. Ch'ng CL, Biswas M, Benton A, et al. Prospective screening for coeliac disease in patients with Graves' hyperthyroidism using anti-gliadin and tissue transglutaminase antibodies. Clin Endocrinol (Oxf) 2005; 62:303.",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_53_42844=[""].join("\n");
var outline_f41_53_42844=null;
var title_f41_53_42845="Bimodal distribution of organ failure in pancreatitis";
var content_f41_53_42845=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F76564&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F76564&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 500px\">",
"   <div class=\"ttl\">",
"    Bimodal distribution of organ failure in pancreatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 480px; height: 258px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bimodal distribution of organ failure in severe acute pancreatitis showing the early organ failure attributable to systemic inflammatory response syndrome and the liberation of inflammatory cytokines and the late organ failure predominately attributable to infection in necrosis and sepsis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_53_42845=[""].join("\n");
var outline_f41_53_42845=null;
var title_f41_53_42846="Gram stain CSF 6";
var content_f41_53_42846=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F65656&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F65656&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gram stain CSF 6",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 368px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_53_42846=[""].join("\n");
var outline_f41_53_42846=null;
var title_f41_53_42847="Bone scan multiple bone mets";
var content_f41_53_42847=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F80098&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F80098&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Metastatic bone disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 376px; height: 523px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A conventional isotope bone scan using technetium 99m MDP demonstrates multiple sites of abnormally increased skeletal uptake.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Daniel Rosenthal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_53_42847=[""].join("\n");
var outline_f41_53_42847=null;
